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The association between certain acute infections and long-term complications is well 
known, with gastroenteritis and subsequent irritable bowel syndrome (IBS) as one 
established example. In 2004 there was a large outbreak of Giardia lamblia in Bergen, 
Norway, due to contaminated drinking-water. An estimated 5000 inhabitants fell ill 
with giardiasis. Before this outbreak, the knowledge on long-term complications 
following giardiasis was scarce.  
Aims 
The overall aim of the studies constituting this thesis was to investigate long-term 
consequences of having had a Giardia lamblia infection in 2004. 
Methods 
All three papers in this thesis are reports from a controlled cohort study. In Bergen, 
Norway, 1252 persons had a verified Giardia lamblia infection by detection of cysts in 
their stools during the outbreak. These were defined as the exposed population in the 
study and were matched 2:1 on sex and age to a control group from the Bergen area. 
Questionnaires were mailed to the participants three, six and ten years after the 
outbreak.  
In paper 1 the main outcome was perceived food intolerance and its association with 
exposure to giardiasis three years after the outbreak. We also investigated the relation 
with IBS. Perceived food intolerance was measured by two unvalidated questions. IBS 
was defined by the Rome III criteria.  
In paper 2 the main outcomes were IBS and chronic fatigue (CF). We investigated the 
association between giardiasis and IBS/CF ten years later, and changes in prevalence 
from three to ten and six to ten years. CF was defined by the Fatigue Questionnaire. 
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In paper 3 the main outcome was quality of life (QoL), as measured by the short-form 
12 version 2. We investigated the association between giardiasis and QoL ten years 
later, and further, the relationship with IBS/CF.  
Results 
Response rates among exposed were 66%, 61% and 50% after three, six and ten years, 
respectively. Among controls the corresponding numbers were 35%, 36% and 30%. 
Perceived food intolerance three years after the outbreak was associated with 
giardiasis, with an adjusted odds ratio (aOR) of 2.00 (95% confidence interval (CI) 
1.65 to 2.42), as compared to the control group. Dairy products was the most 
frequently reported intolerance, with an aOR for exposure of 1.95 (95% CI 1.51 to 
2.51). We found no interaction between exposure to giardiasis and IBS on perceived 
food intolerance in stratified analyses.  
We found a prevalence of IBS after ten years that was 43% (248/576) among exposed 
and 14% (94/685) among controls (aOR 4.74; 95% CI: 3.61 to 6.23). For CF the 
prevalence was 26% (153/587) and 11% (73/692), respectively (aOR 3.01; 95% CI 
2.22 to 4.08). There were no changes in the prevalence of IBS among the exposed 
from six (40%) to ten (43%) years (aOR for the change 1.03; 95% CI: 0.87 to 1.22). 
The prevalence of CF decreased from 31% to 26% among exposed from six to ten 
years (aOR for the change 0.74; 95% CI: 0.61 to 0.90). 
Exposure to giardiasis was associated with a lower QoL. The mean physical 
component summary T-score among the exposed (51.4; 95% CI: 50.6-52.1) was 2.8 
points (95% CI: −3.8 to −1.9; P < 0.001) lower than among controls (54.2; 95% CI: 
53.7-54.8). The mean mental component summary T-score was also 2.8 points (95% 
CI: −3.8 to −1.9, P < 0.001) lower among the exposed (48.9; 95% CI: 48.2-49.6) than 
among controls (51.7; 95% CI: 51.1-52.4). Adjusting for IBS and CF in regression 
analyses resulted in no effect of Giardia exposure on the physical component T-score, 
with an estimated difference of -0.5 points (95% CI: -1.4 to 0.40; P-value: 0.28). 
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Corresponding numbers for the mental component summary in this model were -0.75 
(95% CI: −1.7 to 0.22; P-value: 0.13). 
Discussion 
We found that giardiasis was associated with perceived food intolerance after three 
years. This is a novel finding. Stratified analyses with IBS and exposure status as 
independent variables and perceived food intolerance as the outcome indicated a 
strong association between IBS and food intolerance. The association between IBS 
and food intolerance is well established, and our findings were relatively consistent 
with findings from other studies.  
The strong association between giardiasis and both IBS and CF ten years after the 
outbreak is surprising and unprecedented in the literature on long-term complications 
after gastroenteritis. The prevalence of IBS was unchanged from six to ten years, 
contrary to findings from studies on bacterial gastroenteritis, where post-infectious 
IBS has been found to subside with time. 
The lower QoL among exposed than controls was statistically significant, but the 
clinical significance is questionable. We found no effect of exposure on QoL after 
adjusting for IBS and CF, indicating that these complications were the basis for the 
reduced QoL among the exposed.  
The main methodological problems with our data were the low response rate among 
the exposed after ten years, and the consistently low response rates among controls, as 
well as a lack of baseline information about study participants. Analyses were 
performed to assess selection bias, and the main results from paper 2 would be 
significant even in the unlikely event of an extreme selection bias. A strength of all the 
studies was the high number of participants and the inclusion of a control group. 
Conclusions 
Exposure to Giardia lamblia was associated with long-term complications up to ten 
years later.  
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1. Background 
1.1 Giardia lamblia 
1.1.1 Microbiology and epidemiology 
Giardia lamblia (G duodenalis and G intestinalis are synonyms) is one of six species 
of the parasite Giardia. It is further divided into eight assemblages, from A-H. Only 
Giardia lamblia assemblages A and B can cause infection (giardiasis) in humans (1). 
This protozoan is rather ubiquitous and is the most common waterborne parasitic 
cause of gastroenteritis in humans worldwide. There are an estimated 280 million 
infections every year, and giardiasis is considered by the WHO to be a neglected 
disease (1). The prevalence of infection in developing countries varies from 20-30%, 
and in developed countries from 3-7% (2). A possible cause of the higher prevalence 
of giardiasis in developing countries might be lower sanitation standards. Farthing et al 
also discuss the possibility that healthy children in affluent areas might be more 
resilient towards infection than poor, underprivileged children (3). The prevalence and 
incidence of giardiasis as sporadic cases is probably underestimated in Norway (4), 
and smaller outbreaks may also go unnoticed by the authorities (5). There were 485 
cases of giardiasis in Norway in 2017, giving an incidence rate of 9.22 per 100 000. 
254 of the 485 cases (52.4%) were infected abroad, 130 (26.8%) in Norway, and for 
101 (20.8%) patients the location was unknown (6). A meta-analysis by Hörman et al 
estimated the prevalence of Giardia cases in the asymptomatic (with no symptoms of 
gastroenteritis) general population to be 2.97% in the Nordic countries (Denmark, 
Finland, Norway and Sweden). The prevalence among cases with symptoms of 
gastroenteritis was 5.81% (7). Giardiasis in Norway has historically been considered 
mainly a problem of returned travellers and immigrants. It has not been routine for 
primary care doctors to request stool analysis for Giardia cysts when investigating 
gastroenteritis, nor for the laboratories to investigate for cysts without explicit requests 
from the clinician (4). The last years however, have seen an increase in the reported 
instances of giardiasis in Norway, with a provisional top in 2017. One of the main 
reasons for the increase is the increasing utilisation of the PCR-technique for 
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diagnosing giardiasis. This method is both more sensitive than microscopy of cysts 
(the standard method for many years), and less laborious, leading the laboratories to 
investigate for Giardia more frequently (6). Whether or not there has been an actual 
rise in prevalence (not just increasing diagnostic activity) is not clear. In a review from 
2013, Lal et al discussed the potential effects of environmental change on the 
transmission of Giardia (8). It is difficult to predict what the sum of all the effects will 
be in terms of incidence of giardiasis, but it will be affected, and increasing global 
temperature might introduce giardiasis to areas previously too cold for it to be a 
significant public health-concern.  
Giardia lamblia has some features that explains both why it is widespread around the 
globe, and why it is such a common cause of gastroenteritis. It can persist for long 
periods in various environments including water and food and has a high probability of 
infection even at low doses of ingestion (8). The cysts are resistant to some water 
treatment techniques, like chlorination (9), and the parasite can use both humans and 
Figure 1 Giardia lamblia in the trophozoite form (red arrow) in the duodenal mucosa of a 
human subject. Photo: Kurt Hanevik 
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animals as reservoirs (1). The parasite has a simple life cycle with two stages. It 
survives outside the host as an infectious cyst. It is stimulated to enter the proliferating 
trophozoite form after being exposed to acid in the stomach, and bile and trypsin in the 
duodenum (Figure 1).  It forms into a cyst again after encountering environmental 
changes more distal in the small intestine (10). The trophozoite form has an adhesive 
disc fastening it to epithelial cells in the intestinal lumen, resisting peristaltic expulsion 
(11). The parasite is non-invasive, but causes apoptosis to intestinal epithelial cells, 
increased intestinal permeability and increased hypermotility (10). The mode of 
transmission is through ingestion of cysts, and transmission routes (sporadic cases or 
outbreaks) typically include day-care centres, untreated drinking waters, treated tap 
water, swallowing water in swimming pools, recreational fresh-water contact, 
contaminated foods, person-to-person, animal contact and sexual activity (12). 
1.1.2 Clinical features and treatment 
Typical symptoms of acute giardiasis include diarrhoea, flatulence, bloating, 
abdominal pain and weight loss (10,13), but Giardia infections can also be 
asymptomatic (13). The incubation period is typically 6-15 days (10). The infection 
can be self-limiting, but chronic infection and re-infection also occur (2). When the 
symptoms are less pronounced, and perhaps only diarrhoea is present, the diagnosis 
can be severely delayed (13). Other causes of chronic diarrhoea are more common, 
and chronic giardiasis might not spring to the clinicians’ mind. Metronidazole is the 
first line of treatment, with an efficacy ranging from 60 to 90%, and in the case of 
treatment failure on metronidazole monotherapy a combination of antibiotics is 
recommended (14).  
1.1.3 Post-giardiasis complications 
Giardiasis has been known to be associated with a range of both intestinal and extra-
intestinal complications, some of which are related to ongoing infection and relieved 
after eradication of the parasite (myopathy and skin allergies). Rarer extra-intestinal 
complications include ocular pathologies and arthritis. Other complications are related 
to chronic giardiasis and can persist even long after successful eradication of the 
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parasite (nutritional deficiencies, failure to thrive, stunting and impaired cognitive 
functioning in children) (2).  
In 2004 there was an outbreak of giardiasis in Bergen, the largest waterborne outbreak 
of any kind ever recorded in modern times in Norway (4). A total of 1252 patients had 
a laboratory verified diagnosis by detection of Giardia cysts in their stools (15). The 
capacity of the laboratory receiving stool samples was limited, and at a point during 
the outbreak patients with clinically certain giardiasis were treated with metronidazole 
without laboratory-verification (two letters from the municipal medical officer dated 
November 5th and 10th, 2004). An estimated 2500 people were treated for giardiasis 
during the outbreak (9). This outbreak has been extensively studied, and previously 
unknown long-term complications to giardiasis have been documented. Questionnaire 
studies of the cohort of 1252 patients with laboratory-verified giardiasis and a control 
group have been performed, as well as smaller questionnaire studies and clinical 
studies on sub-populations of patients from the outbreak. A higher prevalence among 
the Giardia exposed (as compared to a control group) of irritable bowel syndrome 
(IBS) and chronic fatigue (CF) has been found both 3 years (15) and 6 years (16) after 
the epidemic. Another study by Wensaas et al on the same cohort found a higher 
prevalence of functional dyspepsia, bloating, diarrhoea, nausea and foul-smelling 
stool/flatulence 3 years after the epidemic as compared with the control group (17). 
Persson et al found an increased prevalence of functional dyspepsia and overactive 
bladder syndrome among the exposed after six years (18), but the association between 
exposure and overactive bladder syndrome disappeared when correcting for IBS, 
functional dyspepsia and CF. Hunskar et al found that Giardia exposure was 
independently associated with daytime sleepiness and a larger sleep need (19), 
whereas another study found no association between asthma and atopy and 
development of post-infectious IBS (PI-IBS) or CF (20). Naess et al reported that the 
prevalence of post-infectious fatigue corresponding to a clinical entity similar to 
chronic fatigue syndrome (CFS) was at least eight times higher than the prevalence in 
two normal populations (21). The cases in that study all had laboratory verified 
giardiasis during the 2004 Bergen outbreak and were included between August 2005 
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and September 2007, after being referred to a chronic fatigue clinic at the Department 
of Neurology, Haukeland University Hospital. Morch et al also concluded that 
exposure to Giardia lamblia was probably associated with CFS five years later (22). 
1.1.4 Possible mechanisms for the post-giardiasis complications 
How a parasite that does not invade the epithelium and causes no readily apparent 
inflammation (23) can cause long-term complications is only partly understood. An 
old study from 1977 raised hypotheses about the role of the bacterial flora (in this case 
bacterial overgrowth in the small intestine) and deconjugated bile salts (24), and a 
more recent experimental study on dysbiosis and Giardia lamblia lend support to a 
role of disturbances of the microbiota (25). Clinical studies from the Bergen Giardia 
outbreak shed more light on possible mechanisms. Hanevik et al found duodenitis in 
patients with chronic giardiasis and abdominal complaints, that subsided with time. 
Some of the controls in that study (Giardia-infected patients where the infection was 
successfully treated) with similar abdominal complaints also had signs of duodenitis. 
The investigations in this study could, however, not establish a cause of the prolonged 
abdominal complaints (26). Another study by Hanevik et al found an increased CD8 
T-cell count in prior Giardia cases with functional gastrointestinal diseases and a 
decreased level of natural killer cells in patients with CFS (27). This could indicate 
abnormal immunological function in post-infectious functional gastrointestinal 
diseases and CFS. Cytokines have been implicated in CFS (28), PI-IBS (23) and in 
giardiasis (29). Patients with CFS have been shown to have an altered gut microbiome 
with reduced diversity, which in turn might dysregulate parts of the immune system 
(30). Another study from Hanevik et al reported a differing cytokine profile between 
Giardia exposed and unexposed, but not between Giardia exposed with CFS and 
Giardia exposed without CFS, except for one of the measured cytokines (sCD40L) 
(31). Dizdar et al found that patients with PI-IBS after giardiasis had increased levels 
of cholecystokinin cells and reduced levels of enterochromaffin cells, as well as a 
lower plasma level of 5-HIAA, a metabolite of serotonin. They were compared with a 
control group of persons who recovered from Giardia with no PI-IBS (32). The 
finding of a lower number of enterochromaffin cells is the opposite of findings in a 
study by Dunlop et al (33). Another study by Dizdar et al found increased visceral 
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hypersensitivity in patients with PI-IBS as compared to controls without PI-IBS, but 
no effect on this hypersensitivity by the serotonin-antagonist ondasentron (34). 
Finally, Dizdar et al found prolonged alterations in duodenal mucosal lymphocytes in 
chronic giardiasis, with a similar pattern both among patients with post-infectious 
functional gastrointestinal disease-symptoms and among previous giardiasis patients 
without such symptoms. This pattern normalized to one similar to non-exposed 
healthy controls with time (35). Although some studies have found an association 
between small intestinal bacterial overgrowth as measured by the lactulose breath test 
and IBS, Morken et al could not replicate this among Giardia sufferers with PI-IBS 
(36).  
To sum up, research originating from the 2004 Bergen Giardia outbreak has 
established a strong association between giardiasis exposure and IBS, CF and 
functional dyspepsia. Clinical studies have shown some immunological variation 
between various study groups, but no clear-cut cause or plausible mechanism of the 
prolonged symptoms have been established.  
1.2 Medically unexplained symptoms 
Medically unexplained symptoms (MUS), medically unexplained physical symptoms, 
medically unexplained physical signs/symptoms, functional disorders, functional 
somatic syndromes, bodily distress/stress syndrome/disorder, somatic symptom 
disorder, psychophysical/psychophysiological disorder, psychosomatic disorder, 
symptom defined illness/syndrome, somatoform disorder, complex physical 
symptoms, persistent physical symptoms, functional symptoms (37–39) are some of 
the terms that have been in use or have been proposed to be used to describe the 
situation when the patient has symptoms/complaints that cannot be adequately 
explained by evidence of organic disease (40). There has been some debate in the 
scientific community what to call such illnesses (37–39), and if a generic term is 
useful at all (37,41). Creed et al suggested ten criteria to judge the value of terms that 
could be used instead of MUS. They proposed that the term should: be acceptable to 
patients, be acceptable and useful for doctors and other health care professionals, not 
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reinforce dualistic thinking, be usable for patients with comorbid organic disease, have 
a clear core theoretical concept, facilitate multi-disciplinary treatment, have similar 
cross-cultural meaning, be neutral on aetiology and pathology and have a satisfactory 
acronym (38). Marks et al performed an online survey among healthy lay-persons 
investigating which of seven terms to describe MUS they deemed most appropriate. 
The most popular term was “Persistent Physical Symptoms,” (20%) whereas “MUS” 
was preferred by 15%, and 24% had no particular preference (37).  
It has been pointed out that many of the medical subspecialties deal with at least one 
functional syndrome, including IBS (gastroenterology), CFS (infectious disease) and 
fibromyalgia (rheumatology) (41). Wessely argued that there was considerable overlap 
between many of the functional somatic syndromes (or MUS) including 
epidemiological characteristics, proposed mechanisms, comorbidity with anxiety and 
depression and treatment options (41). In the same interesting exchange of opinions, 
White argued that this “lumping” together of illnesses supports a mind/body dualism, 
and that the various above-mentioned overlaps are not as convincing (and that the rates 
of overlap are lower in primary care), and that “splitting” of illnesses have resulted in 
more scientific progress than lumping (41).   
The term “MUS” might be slightly misleading. Although no complete understanding 
of the pathogenesis of the various conditions covered by the term exist, there has been 
an advance in the research on the aetiology and pathogenesis of many of the 
conditions, as outlined for IBS and CFS in the below sections. Explanations for the 
patients’ conditions can have a therapeutic effect in itself, even when they are 
incomplete (39). 
Regardless of what the illnesses are called and how they are categorized, the suffering 
is real. The MUS conditions can affect quality of life (QoL) profoundly, as 
exemplified by the lower QoL among patients with IBS and CFS as compared to 
healthy subjects (42–46). QoL measures are important in organic diseases such as 
diabetes and rheumatoid arthritis, and perhaps especially in illnesses where biomarkers 
 18
to monitor illness progress or treatment effect are lacking, such as the MUS 
conditions.  
1.3 Irritable bowel syndrome 
1.3.1 Epidemiology, aetiology and pathogenesis 
IBS is a functional gastrointestinal disorder, where the term “functional” refers to the 
lack of consistent signs of organic disease (i.e. no biomarker) (47,48). The hallmark of 
IBS is abdominal pain or discomfort with association to defecation and/or stool 
changes, with a duration of symptoms of six months or more (49). IBS is associated 
with decreased work productivity (50), high use of health care resources (50,51) and 
reduced quality of life (42,43,45,46). The global pooled prevalence of IBS is 11% 
(52), and a study from Norway in 2006 found the prevalence to be 8% using the Rome 
II criteria (53). The risk factor with the most documentation is female sex (54), with a 
female to male ratio of 2-2.5 to 1 (55). There is a declining incidence of IBS with 
increasing age (54). Other risk factors are summarized in a comprehensive review by 
Enck et al and include (but are not limited to) psychological factors like stress, 
anxiety, depression and somatization, somatic issues like gastrointestinal infection, 
pain and endometriosis, and social conditions (54). 
Although IBS has been recognised for decades, debate still exist whether this 
condition is one disease or many. Differential diagnoses include the inflammatory 
bowel diseases, celiac disease, lactose intolerance and microscopic colitis (51). Prior 
to the development of adequate diagnostic tools, patients with these diseases might 
have been diagnosed with IBS. Many pathogenetic factors have been studied, but still 
no unifying theory for the pathogenesis of IBS exists. Disturbed gastrointestinal 
motility and visceral hypersensitivity are some of the pathophysiological factors that 
have been known for a while (56). Evidence of various forms of immune activation 
and inflammation and low-grade post-infectious inflammation is mounting, as well as 
a role of genes, bile-acid malabsorption and diet (56,57). The fact that the brain 
influences the gut has also been established in the literature (56,57), supported by 
evidence of the efficacy of psychological interventions on IBS-symptoms (47) and the 
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close relation between anxiety, depression and stress and IBS (58). More recently, the 
idea that the gut influences the brain has also gained interest, although the strongest 
evidence for this hypothesis stems from animal research. Still, there are numerous 
ways that the microbiota might communicate with the enteric- as well as the central 
nervous system (59). Also, recent longitudinal studies found that IBS precedes anxiety 
and depression in some patients, which might indicate that bowel disturbances could 
be causative factors in developing these illnesses, not just the other way around (57). 
The use of probiotics (microorganisms with a purported beneficial effect on health) in 
IBS has shown a moderate but consistent effect on relieving abdominal symptoms 
(60). How alterations of the human microbiota might affect human behaviour is an 
interesting subject for future research.  
1.3.2 How to define and diagnose IBS 
According to clinical guidelines and researchers on IBS, it is reasonably safe to make a 
diagnosis of IBS based on the Rome criteria without extensive testing, in absence of 
alarming features indicating organic disease (51). Despite this, a survey from 2017 
found that only 32 % of general practitioners across Europe make a diagnosis of IBS 
based on symptoms only (without further testing). Only 36 % of general practitioners 
use the Rome criteria when diagnosing IBS (61). A study by Spiegel et al (2010) 
found that 72% of a group consisting of community gastroenterologists, general 
internal medicine physicians and nurse practitioners endorsed IBS as a diagnosis of 
exclusion (62). The reason for this discrepancy between guidelines and clinical 
practice remains to be resolved.  
Given the lack of objective clinical symptoms or signs of IBS, there has been a 
continuous debate regarding how to define IBS, both in scientific studies and as a 
clinical diagnosis. The first attempt to find a set of criteria to define IBS was made in 
1978 by Manning et al (63), who identified six symptoms based on patient responses 
to a questionnaire that discriminated reasonably well between IBS and organic 
gastrointestinal disease. These criteria were used for more than thirty years (51) and 
Dang et al (2012) argued that they were more valid and accurate than the subsequent 
Rome I-III criteria (64). The Rome I criteria were published in 1990 (65), followed by 
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the Rome II criteria in 1999 
(66), and the Rome III criteria 
in 2006 (49). Similar for all 
four sets of criteria was the 
presence of abdominal pain (or 
discomfort in Rome I-III) and a 
relation to change in stool form 
or frequency as well as relief of 
pain (or discomfort) upon 
defecation. The required 
duration and frequency of the 
symptoms also differed 
somewhat between the criteria. 
The Manning criteria and the 
Rome I criteria also included criteria about passage of mucus, abdominal distension 
and altered passage of the stools not found in Rome II or III. Ford et al did a 
comprehensive validation study of the Rome III criteria in 2013 and found an overlap 
between the four above mentioned criteria of 47.5% (Figure 2 (67)). The Rome III 
criteria were found to perform only moderately in predicting an IBS-diagnosis. The 
reference (“gold”) standard in this study for the definition of IBS was the presence of 
abdominal pain/discomfort associated with altered bowel habit and an absence of 
organic gastrointestinal disease (including negative endoscopies as indicated) (67).  
In 2016 the Rome IV criteria were released, and the main differences from the Rome 
III criteria regarding IBS were 1) the removal of the term “discomfort” from the 
definition, 2) the presence of pain at least once a week as opposed to three times per 
month and 3) abdominal pain that is related to defecation as opposed to improved with 
defecation (68). The new criteria were validated before release, and a prevalence of 
IBS of 5.7% was found in the reference population using the Rome IV criteria as 
compared to 10.7% using Rome III. Point 2 above made the largest impact in lowering 
the prevalence of IBS (69). In the project from which this thesis springs out, we used 
Figure 2 Overlap between the Manning criteria and 
the Rome I-III criteria. With permission from A.C 
Ford et al 
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the Rome III criteria to define IBS. According to these criteria, IBS can be further 
classified into diarrhoea or constipation predominant, mixed or unsubtyped (49).  
PI-IBS is defined using the same criteria as for sporadic IBS and hence in most 
respects is clinically similar to sporadic IBS, although Dunlop et al found that 
diarrhoea was more common among PI-IBS individuals than among individuals with 
IBS of unknown origin. They also had less psychiatric illness, and an increased 
number of serotonin-containing enterochromaffin-cells (33). IBS and PI-IBS patients 
are managed similarly in the clinic (70). 
1.4 Chronic fatigue 
Definitions of fatigue vary, and the prevalence will obviously vary according to the 
strictness of the criteria used to measure fatigue and the population under study. 
Fatigue as a symptom, even when considered chronic (duration six months or longer), 
was highly prevalent both in the general Norwegian population (11%) (71) and in a 
Dutch general population (31%) (72). Both studies were performed in a representative 
population. The Norwegian study used the Fatigue Questionnaire and was performed 
in 1996 (71). How chronic fatigue was defined in the Dutch population was not 
entirely clear, but it was described as a fatigue lasting longer than six months but not 
meeting the CDC-94 criteria for CFS. It was performed in 2003 (72). In USA, 24% of 
patients attending primary care considered fatigue a "major problem" (73). CF 
accompany various diseases, both somatic and psychiatric (71). 
CF is an important part of the more strictly defined CFS. CFS is a clinical diagnosis, 
which depends on exclusion of relevant causes for fatigue. Various criteria exist, and 
some are also used in questionnaire studies without clinical assessment (74). One 
estimate based on the CDC-1994/Fukuda criteria found a prevalence of self-assessed 
CFS to be 3.3% whereas clinically assessed CFS had a prevalence of 0.76% (74). A 
study on fatigue in the Dutch general population found that there were similarities in 
the lifestyles among patients classified by different definitions of fatigue (short-term 
fatigue, CF and CFS according to CDC-94 criteria) and hypothesised that these 
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different forms of fatigue were not necessarily different types of disorders, but 
different manifestations on a continuum of fatigue (72).  
The pathogenesis of CFS is far from completely understood, but there is accumulating 
evidence for immunological disturbances associated with the condition. Whether these 
disturbances are the cause or the effect of the conditions is not yet established (75). A 
recent study by Naviaux et al found a metabolic response among CFS-sufferers that 
was homogenous and statistically robust (76). Infections such as the Epstein-Barr 
virus, Q fever and viral meningitis have been associated with an increased risk of CFS 
(77).  
Fatigue is also a common symptom in chronic gastrointestinal disease (78,79), and 
previous studies from our group has found considerable overlap between IBS and CF 
among patients with previous giardiasis (15,16). 
1.5 Food hypersensitivity 
Food hypersensitivity means that the patient has an adverse reaction to food. 
Hypersensitivities can be divided into food allergies that are immunologic in origin 
(IgE or non-IgE mediated, or a mixed type) and food intolerances, that are non-
immunologic (80). This classification misses celiac disease, that although it is of 
immunologic origin, is not normally classified as an allergy (81).  
1.5.1 Food allergy 
The true prevalence of food allergies is uncertain, and estimates vary according to 
definitions, populations and methodology, and self-reports probably overestimate the 
prevalence (82). It is more common in preschool children (4-7%) than among adults 
(1-2%) (81). The most common allergies in children are to cow’s milk, egg, peanut, 
soy, tree nut and shellfish, and for adults it is peanut, tree nut and seafood (81). There 
is no clear evidence of an association between food allergy and IBS (83). 
Ideally, an IgE-mediated food allergy is diagnosed based on anamnestic information 
about adverse reactions to the culprit food, followed by remission upon removal of the 
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food from the diet, and confirmation by a positive serum IgE test and maybe also a 
positive skin prick test (81).  
1.5.2 Celiac disease 
Celiac disease is an immune-mediated reaction to gluten, affecting about 1.5% of the 
population in Northern Europe. Simona et al proposes that four out of the following 
five criteria should be met to diagnose celiac disease: anamnestic information 
compatible with the disease, presence of serum-autoantibodies, positivity for HLA-
DQ2 or DQ8, duodenal biopsy and symptom-improvement when adhering to a gluten 
free diet (84).  
1.5.3 Food intolerance 
Up to 15-20% of the general population report food intolerance. These intolerances 
can be divided by purported origin into: 1) pharmacologically mediated intolerances 
(salicylates, amines, glutamates, caffeine), 2) intolerances based on enzyme or 
transport defects (lactase dehydrogenase deficiency), and 3) unknown origin, including 
the incompletely understood non-celiac gluten sensitivity (85).  
Hydrogen/methane breath tests assessing carbohydrate malabsorption exist, but their 
clinical usefulness in detecting intolerance to various groups of carbohydrates is 
questionable. Apart from these tests, there are no validated objective tests to verify the 
various food intolerances (85), which can be frustrating for both patients and health 
care providers (86).   
1.5.3.1 Food intolerance in IBS 
As many as 70% of individuals with IBS report that different foodstuffs influence their 
symptoms (87), and 90% of persons with self-reported food hypersensitivity had IBS 
in one study (86). A few studies have mapped the foodstuffs patients with IBS report 
to cause symptoms, and some of the culprit foods include: milk, milks products, wheat 
products, caffeine, certain meat, cabbage, onion, peas, beans, hot spices, fried foods 
and smoked products (88). The NICE Guideline for IBS recommends restricting the 
intake of coffee, tea, alcohol and fizzy drinks, reducing the amount of high-fibre food 
and resistant starch and limiting the intake of fruits. Patients with diarrhoea should not 
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ingest sorbitol. If these more general advice fail, patients can try out single food 
avoidance and/or exclusion diets, including the low FODMAP- diet, as advised by a 
healthcare professional with expertise in dietary management (89). FODMAP is an 
acronym for fermentable oligo- di- and monosaccharides and polyols, and these are a 
group of poorly absorbed carbohydrates (90). The low FODMAP-diet has gained a lot 
of interest, and there is an accumulating amount of evidence for its efficacy in 
relieving IBS-symptoms in the short-term, whereas long-term effect on microbiota and 
gastrointestinal functioning is uncertain (85,91).  
1.5.3.2 Food intolerance in chronic fatigue 
The research on food intolerance and fatigue is scarce. One recent review found 17 
studies investigating various dietary and nutrition supplements as treatment for CFS-
symptoms and concluded that there was not enough evidence to recommend modified 
diets for such symptoms (92). IBS is a common comorbidity of CFS, and when IBS is 
present, the dietary advice given for IBS might apply. Berstad el at found that 85% of 
84 patients referred to tertiary care for self-attributed food hypersensitivity had fatigue 
(not CFS). Notably, all but one of the same 84 patients also had IBS (93). Preliminary 
results from our research group indicate an independent association between perceived 
food intolerance and CF, even when adjusting for IBS-status (unpublished data).  
1.6 Quality of life 
Patient reported outcome measures (PROM) are self-report instruments used to assess 
the patient’s perspective on their own health status and treatment (94,95). PROM 
measures can be generic or disease-specific. Generic PROM instruments assess health 
concepts that are relevant to most patient groups and can be used to compare PROM 
between different conditions and healthy persons but will miss some points that are of 
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special interest to specific diseases. These are better assessed by disease-specific 
instruments, which in turn cannot be used to compare different conditions (95).  
Constructs measured by PROMs include QoL, health-related QoL, health status, 
wellbeing (i.e. measures of depression and anxiety), patient satisfaction and symptoms 
and functioning (95).  
The short-form 36 (SF-36) is a PROM that is widely used, and was found to perform 
better than other similar instruments on many of the properties measured in a review 
by Bryan et al (96). The short-form has also been simplified to a shorter version, the 
short-form 12 (SF-12) while retaining good validity (97). It has been cross-validated in 
nine European countries including Norway (98). The SF-12 is referred to in the user 
manual as a measure of “health status” (99), however, Meadows et al state that health 
status is not synonymous with QoL (95). Studies utilizing the SF-36 or SF-12 
nevertheless refer to this measure as assessing health-related quality of life (42), and 
the homepage of the RAND corporation, which distribute the SF-36, classify the SF-
12 and SF-36 as QoL measures (100). 
The last search for literature for this thesis was performed on the 31th of March 2019. 
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2. Aims of the present study 
This thesis is part of a bigger project investigating long-term complications after the 
Giardia lamblia outbreak in Bergen, Norway 2004.  
The aims of the study comprising this thesis were: 
Paper 1: To compare the prevalence of perceived food intolerance among Giardia 
exposed as compared to a control group, and to explore how this was related to the 
presence of irritable bowel syndrome in the two groups. We also aimed to investigate 
the associations between exposure status and content of fermentable oligo- di- and 
monosaccharides and polyols in the reported foods.  
Paper 2: To estimate the prevalence and odds ratio of irritable bowel syndrome and 
chronic fatigue ten years after acute giardiasis as compared to a control group. The 
secondary aims were to investigate changes in prevalence from three to ten and from 
six to ten years and to estimate incidence, recovery, and persistence of these 
conditions. 
Paper 3: To evaluate the association between giardiasis and quality of life ten years 
after the outbreak, as compared to a control group. The secondary aim was to assess 
how quality of life related to irritable bowel syndrome and chronic fatigue in the 
exposed and the control group. 
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3.  Materials and methods 
3.1 Setting and design 
In the autumn of 2004 one of the main drinking water reservoirs of Bergen 
Municipality was contaminated by Giardia lamblia cysts. There were almost 50 000 
individuals registered as recipients of drinking water from this source, in addition to 
facilities typical of a medium sized city (hotels, restaurants, offices, etc) (9). Around 
5 000-6 000 persons were infected with Giardia lamblia cysts, according to an 
external report investigating the outbreak (101). During the period of the outbreak 
1252 patients were identified who also had Giardia lamblia cysts detected in their 
stools. Giardia lamblia is not endemic in Norway and hence this was an outbreak of 
giardiasis in a population that was previously largely unexposed to the parasite. It has 
sometimes been referred to as a “natural experiment,” and an observational 
prospective study with a control group was designed to investigate the clinical 
consequences of the outbreak. The inclusion of a control group was important, because 
many of the complications we planned to investigate were known to have a high 
prevalence in the normal population. Data for all 3 papers were collected by mailed 
questionnaires. For paper 1 data from follow-up three years after the outbreak were 
used. For papers 2 and 3 data from follow-ups at three, six and ten years after the 
outbreak were used.  
3.2 Participants 
The 1252 patients identified with Giardia cysts in their stools constituted the exposed 
group in all three papers (Figure 3). A control group was established by sampling 
individuals from Bergen matched on sex and age. Two controls were selected for each 
of the exposed, resulting in a control group of 2504 individuals. As the controls were 
from the same area as the outbreak took place, a question was included to assess 
whether the controls had been exposed to Giardia infection. Controls who self-
reported a doctor-verified diagnosis of giardiasis in 2004 were excluded. This makes 
misclassification of exposure status less likely. Misclassification of Giardia exposed 
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as controls would bias the results toward the null hypothesis, or, in other words, 
increase the likelihood of a type II error: not finding an association where one exists. 
Due to a low response rate among controls at the three-year follow-up (862/2504; 
34%), questionnaires were sent to an additional 1094 control persons six months later. 
The response rate among these controls was even lower (271/1080; 25%). The 
additional control group was included in paper 1, but not in papers 2 and 3. Papers 2 
and 3 included data from follow-ups three, six and ten years after the outbreak, and for 
the two latter follow-ups no extra controls other than the 2504 original participants 
were contacted by mail.  
For the ten-year follow-up we excluded children under 18 before questionnaires were 
sent. For papers 2 and 3, children who were under 11 and 14 at the three- and six-year 
follow-ups (who had answered the questionnaires), respectively, were therefore 
removed before the analyses. We discussed whether to remove all children below 18 
for the three- and six-year follow-ups as well, but this would lead to more missing 
cases in the longitudinal analyses. Persons who were 11 or more in 2007 or 14 or more 
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3.3 The questionnaires and the variables 
The content of the questionnaires was chosen based on clinical observations from 
doctors during the outbreak, findings from studies of the outbreak and existing 
literature. Table 1 shows the topics investigated. The six uppermost topics in bold font 
are the ones further investigated in papers 1-3. The questionnaires can be found in 
Appendices 2-4. 
3.3.1 Exposure variable 
Giardia lamblia infection was the exposure in all three papers. The exposure variable 
was dichotomic with the categories exposed or control. 
3.3.2 The demographic variables 
Sex and age were obtained from the participants' social security number and were 
considered as confounders for papers 1 and 2. Although obtained after the outbreak, 
 
 
Table 1 Overview of content of the questionnaires sent to participants three, six and ten 
years after the Bergen 2004 Giardia lamblia outbreak 
 Years after Giardia infection 
Theme 3 6 10 
Demographic variables x x x 
Known Giardia infection (controls only) x x x 
Irritable bowel syndrome x x x 
Chronic fatigue x x x 
Food intolerance x   
Health-related quality of life   x 
Pregnant at time of answering questionnaire x x x 
Consent to linkage of response to registry data x x x 
Dyspepsia x x  
Milk intolerance x x  
Sleep x x  
Asthma, allergy x x  
Status as student in 2004 x x  
Abdominal complaints prior to giardiasis (exposed only) x   
Consent to linkage of response to clinical tests x   
Questions about information and treatment x   
Urinary tract symptoms  x  
Fibromyalgia   x 
The six uppermost themes (presented in bold type) are used in the studies comprising this 
thesis 
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these variables should be considered baseline information as they are given by birth. 
Marital status (4 levels), level of education (3 levels) and source of income (recorded 
with 8 levels, categorized to 4 levels) were recorded at each of the three follow-ups, 
and were considered as confounders in all papers. Status as a student was recorded 
after three and six years, and only considered as a confounder in paper 1.  
3.3.3 Irritable bowel syndrome 
Studies from one and two years after the outbreak found a high prevalence of 
abdominal complaints after giardiasis (102,103), but with unvalidated questions used 
in the assessment of gastrointestinal symptoms. It was therefore decided to use the 
Rome III criteria (49) to define IBS in the later follow-ups. These were not validated at 
the time of the planning of this study, but they were based on the Rome II criteria, 
which had been used in prior research on IBS. Also, a working team of renowned 
researchers in the field of functional bowel disorders recommended their usage in 
research on IBS (49). The Rome III criteria were later validated (in 2013) in a study 
performed in Canada by Ford et al (67).   
IBS is defined according to the Rome III criteria as an abdominal pain/discomfort 
present for at least 2-3 days of the last three months, with symptom onset six months 
before the response. At least two out of three additional criteria must also be met: 1) 
improvement of pain/discomfort with defecation; 2) change in frequency of stool at 
onset; 3) change in form (appearance) of stool associated with onset (49). We also 
defined “severe IBS” as IBS that limited daily activities at least often. IBS subtyping 
was performed according to the Rome III criteria also, sub-dividing the participants 
with IBS into IBS with diarrhoea (IBS-D), IBS with constipation (IBS-C), mixed 
(IBS-M), and unsubtyped (IBS-U).  
IBS was investigated as an interacting factor in paper 1, as an outcome in paper 2 and 
as a mediating agent and interacting factor in paper 3.  
3.3.4 Chronic fatigue 
Several patients complained of fatigue in the period after the outbreak. Morch et al 
found a high prevalence of fatigue at 41% based on one question in a study carried out 
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two years after the outbreak. It was therefore decided to investigate this further with a 
validated fatigue questionnaire, and the Fatigue Questionnaire was chosen (104), 
partly because it had been used in a Norwegian general population previously (71). 
The scoring of the Fatigue Questionnaire has been described in detail in paper 2 (105). 
In short, responses on a Likert-type scale were dichotomized, and a total dichotomized 
score of four or more constituted a case of CF, if the symptoms had lasted six months 
or more. Severe CF was defined as CF with a total fatigue score of 23 or more. 
CF was investigated as an outcome in paper 2 and as a mediating agent and interacting 
factor in paper 3.  
3.3.5 Eight-level exposure variable 
For paper 3 we constructed an eight-level variable by combining the dichotomous 
variables exposure status (exposed/control), IBS (yes/no), CF (yes/no). The reference 
category in regression analyses was “neither condition among controls.” The 
remaining categories where: “neither condition among exposed,” “IBS-only among 
controls”, “IBS-only among exposed”, “CF-only among controls”, “CF-only among 
exposed”, “IBS and CF among controls”, and “IBS and CF among exposed”. 
3.3.6 Food intolerance 
Four questions about food were included in the questionnaire sent to the respondents 
after three years. The first two were regarding milk in particular and were not included 
in the analyses in paper 1. The latter two were included. The first of these was an 
unvalidated question regarding ailments from the bowels in relation to foodstuffs, 
phrased as follows (translated from Norwegian): “Do certain types of food give you 
abdominal symptoms?” Possible answers were: None, light, moderate and severe. The 
second question was an open-ended question: “If you react (to food), to what kind is 
that?” The answers to this question were categorized based on categories from the 
literature (88,106–108), and some were made by the research group. Every category 
was accounted for in a codebook. 
Perceived food intolerance, both in general, and according to specific food categories, 
was the main outcome of paper 1.  
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3.3.7 Health-related quality of life 
At the outset of the sub-studies of this thesis, the association between exposure to 
Giardia and IBS and CF had already been established (15,16). IBS (42,43,45,46) and 
CFS (44) has been associated with a reduced QoL in previous studies, but the impact 
of giardiasis on the QoL and, further, the relation with IBS and CF, was unknown. The 
symptom-burden associated with IBS can range from mild (not even leading to contact 
with the healthcare system) to severe (disability), depending on the population 
investigated (i.e. surveys from the normal population, investigations among patients in 
tertiary clinics, etc). It was therefore important to assess how QoL was affected in this 
particular setting.   
The SF-12 version 2 (SF-12v2) was chosen as it is generic, widely used and takes a 
relatively short time to answer for the respondents. The 12 questions assess eight 
domains of health related QoL, that are further compiled to two measures of QoL, the 
physical component summary (PCS) score and the mental component summary 
(MCS) score. Both scores have a theoretical range of 0-100. It is scored by an 
algorithm provided by a commercially available computer programme (99), where a 
normal population from USA inn 2009 is used as a reference. This population has a 
mean PCS and MCS of 50 with a standard deviation (SD) of 10. The calibration of the 
PCS and MCS against an US norm makes comparisons across populations more 
relevant.  
PCS and MCS were the main outcomes for paper 3.  
3.4 Analyses and statistical methods 
3.4.1 Directed acyclic graphs 
We did not have unbiased baseline information about our respondents, other than age 
and sex. The demographic variables marital status, level of education and source of 
income are measured at the same times as the outcomes, at follow-ups three, six and 
ten years after the outbreak. Directed acyclic graphs (DAG) can aid the planning of the 
analyses, by giving a visual representation of the relationships between the study 
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variables. Some of the newer R packages can also use code generated from the 
creation of the DAGs directly in R to test if the DAG is consistent with the dataset 
(109). We only used DAGs as a visual aid for our studies. Figure 4 depicts various 
DAG-models of causality for our study of QoL after ten years (paper 3). Model 1 is 
the most complete (and complex), including unobserved variables depicted as grey 
circles, indicating the lack of baseline information. Model 2 is one of the working 
models we used in the analyses, where marital status, level of education and source of 
income were treated as confounders. Under this model age and sex were excluded as 
the statistical method accounted for the matching of the subjects. Model 3 depicts a 
scenario where IBS an CF are considered mediators of the effect of exposure on QoL. 




Figure 4 Directed acyclic graphs of different models of causality for variables in a study ten years after a 2004 
Giardia lamblia outbreak in Bergen, Norway 
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3.4.2 Analyses 
Descriptive statistics were calculated as percentage or mean for papers 1-3, and for 
some of the data in paper 3 we also calculated the SD and 95% confidence intervals 
(CI).  
 
Differences between proportions were tested with Pearson’s chi square exact 2-sided 
test for all categorical variables in paper 1. In papers 2 and 3 we used Pearson’s chi 
square exact 2-sided test for categorical multilevel outcomes and Fisher’s exact 2-
sided mid-p test for binary outcomes (110). Student’s t-test was used for analyses of 
age as a continuous variable in papers 1 and 2. Since the exposure and control group 
were matched for sex and age, testing for differences for these variables could be 
considered superfluous, and hence were not performed in paper 3.  
 
In paper 1 and 2 we used standard logistic regression analyses for the outcomes 
perceived food intolerance (paper 1) and IBS and CF (paper 2). For the changes in 
prevalence over time for IBS and CF in paper 2, we used generalised estimating 
equations as this regression-method accounts for the correlation between repeated 
measures and the matched design. For the main outcomes in paper 3, we used mixed 
models, another regression method that accounts for the matching of the subjects.  
 
Interactions were investigated using the Breslow-Day test for homogeneity of the odds 
ratios (OR), and with the appropriate regression method when applicable. 
Confounding was investigated, and adjusted for when necessary, in regression models.  
 
All tests were two-sided with the level of statistical significance set to 0.05. The 
analyses were done using IBM SPSS Statistics for Windows, version 22 (paper 1), 
version 24 (paper 2) and version 25 (paper 3). Sankey diagrams used for Figure 1 in 
paper 2 were plotted using R (111) with the package sankeyD3 (112). The causal 
models in Figure 4 in this thesis were made using the web application DAGgity (109). 
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3.5 Ethical approval 
Paper 1 was approved by the Regional Committee for Medical and Health Research 
Ethics (project 150.07) and by the Ombudsman for Privacy in Research, Norwegian 
Social Science Data Services (project 17014). Papers 2 and 3 were approved by the 
Regional Committee for Ethics in Medical Research (ref.no. 2014/1372).   
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4. Results 
The response rates in the three papers are presented in Table 2. The same cohort has 
been studied at three follow-ups. There are some differences between paper 1 and 
papers 2 and 3 for the three-year follow-up data, because of the exclusion of the 
second control group and children aged 10 and below for papers 2 and 3. The response 
rate among the exposed had declined at each follow-up, whereas the control group had 
a similar response rate at three and six years but dropped at ten years. These changes 
have not been tested for statistical significance. 
 
4.1 Paper 1 
The prevalence of perceived food intolerance was high both among the exposed 
(63.9%) and among controls (47.6%). The adjusted odds ratio (aOR) for perceived 
food intolerance for the exposed group was 2.00 with 95% CI: 1.65 to 2.42, as 
compared to the control group (Table 3). Perceived intolerance for dairy products was 
the most frequently reported intolerance, with an aOR for the exposed of 1.95 (95% 
CI: 1.51 to 2.51). Perceived intolerance for fatty foods, vegetables, fruit, cereals and 
alcohol was also significantly higher in the exposed group. The groups did not differ in 
perceived intolerance to spicy foods, coffee or soda. In stratified analyses the 
association between exposure to giardiasis and perceived food intolerance was 
significant within the no-IBS group (aOR 1.36; 95% CI: 1.07 to 1.72), whereas within 
the IBS group it was not (aOR 1.25; 95% CI 0.78 to 2.01). The difference was small, 
and the Breslow-Day test for homogeneity of the OR was not significant. Perceived 
intolerance for high FODMAP foods (aOR 1.91; 95% CI: 1.57 to 2.33) and low 
 
Table 2 Response rate per year in exposed and control cohort three, six and ten years after 
a Giardia lamblia outbreak in Bergen, Norway, 2004 
  Years after giardiasis 
 
Three years 
(paper 1)  
Three years 
(papers 2 and 3)  
Six years 
(papers 2 and 3)  
Ten years 
(papers 2 and 3) 
Group n N %  n N %  n N %  n N % 
Exposed 817 1252 65.3  802 1218 65.8  731 1205 60.7  592 1176 50.3 
Control 1128 3598 31.4   843 2436 34.6   852 2378 35.8   708 2330 30.4  
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FODMAP foods (aOR 1.55; 95% CI: 1.26 to 1.92) were both associated with exposure 
status. 
A wide variety of foods were mentioned, and the categories made were (number of 
respondents who mentioned foods in the category in parenthesis): Dairy products 
(292), spicy foods (256), vegetables (232), cereals (227), milk (163), fruit (120), 
alcohol (109), meats (93), coffee (91), fatty foods (75), wheat (73), unclassified (46), 
sweets (45), soda (40), sugar (33), dinners (29), gravy/dressing (28), beer (26), 
chocolate (25), juice (25), eggs (23), baked goods (22), fish (21), shellfish (21), yeast 
products (18), smoked food (17), nuts (17), processed food (15), tomato/tomato 
products (15), fruit juice (14), gluten (11), fibre (8), tea (8), salted food (8), soy (3).  
 	
 
Table 3 Perceived food intolerance according to food categories and FODMAP content in 817 
Giardia exposed and 1128 controls three years after an outbreak of giardiasis in Bergen, Norway, 
2004. (This table is a modified version of the tables from the original article). 
 Exposed 
N = 817 
 Controls 
N =1128 
  Adjustedc 
Category n %  n %   ORd 95% CI 
Yes to question on food 
intolerance in generala 488 63.9
a  524 47.6a   2.00 1.65 to 2.42 
          
Food categoriesb          
   Dairy products 163 20.0  129 11.4   1.95 1.51 to 2.51 
   Spicy foods 119 14.6  137 12.1   1.25 0.96 to 1.63 
   Fatty foods 48 5.9  27 2.4   2.63 1.62 to 4.26 
   Vegetables 118 14.4  114 10.1   1.56 1.18 to 2.06 
   Fruit 75 9.2  45 4.0   2.45 1.67 to 3.60 
   Cereals 128 15.7  99 8.8   1.98 1.49 to 2.62 
   Alcohol 66 8.1  43 3.8   2.29 1.54 to 3.40 
   Coffee 39 4.8  52 4.6   1.05 0.68 to 1.61 
   Soda 17 2.1  23 2.0   1.03 0.55 to 1.94 
          
FODMAP contente          
   High FODMAP 308 37.7  277 24.6   1.91 1.57 to 2.33 
   Low FODMAP 230 28.2  231 20.5   1.55 1.26 to 1.92 
Abbreviations: FODMAP: fermentable oligo- di- and monosaccharides and polyols; IBS: irritable 
bowel syndrome; CI: confidence interval; OR: Odds ratio. 
a Question A, with total n = 764 for exposed and n = 1100 for controls; 
b Question B: “If you react (to food), to what kind is that?”; 
c Adjusted for sex and age; 
d Statistically significant ORs are presented in bold font; 
e Assumed FODMAP content of the response(s) to question B 
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4.2 Paper 2 
The prevalence of IBS (Figure 5) after ten years was 43% (248/576) among exposed 
and 14% (94/685) among controls (aOR 4.74; 95% CI: 3.61 to 6.23). For CF the 
prevalence was 26% (153/587) and 11% (73/692), respectively (aOR 3.01; 95% CI: 
2.22 to 4.08). The prevalence of IBS among the exposed was unchanged from six 
(40%) to ten (43%) years (aOR for the change 1.03; 95% CI: 0.87 to 1.22). There was 
a decrease in prevalence both from three (47%) to ten years (aOR for the change 0.75; 
95% CI: 0.63 to 0.90) and from three to six years (aOR for the change 0.73; 95% CI: 






















3 years 6 years 10 years
 IBS among exposed  IBS among controls
 CF among exposed  CF among controls
Prevalence
Figure 5 Changes in prevalence of irritable bowel syndrome (IBS) and chronic fatigue (CF) three, 
six and ten years after a Giardia lamblia outbreak in Bergen, Norway 2004 
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six to ten years (aOR for the change 0.74; 95% CI: 0.61 to 0.90). The prevalence also 
decreased from three (47%) to ten years (aOR for the change 0.40; 95% CI: 0.33–
0.48), and from three to six years (aOR for the change of 0.53; 95% CI: 0.46–0.62). 
There were no changes in prevalence of IBS or CF for any of the periods among 
controls. The results for the prevalence and time changes from three to six years have 
been published previously by Hanevik et al (16), but were calculated anew for our 
study, because of a slightly changed study population. The results were nonetheless 
similar.  
We also investigated the different possible trajectories of IBS and CF among the 
subgroups with valid answers at all years and found that there was a considerable flow 
in and out of the two conditions over the years. Persistent IBS (IBS that was present at 
all three follow-ups) was strongly associated with exposure to Giardia, with an aOR of 
19.3 (95% CI: 8.3 to 44.7). Stability of the IBS subtype was low. 
4.3 Paper 3 
QoL was measured with two scales, one for physical QoL (PCS), and one for mental 
QoL (MCS). The mean PCS T-score for the entire cohort regardless of group was 52.9 
(SD: 8.7) and for MCS it was 50.4 (SD: 9.1).  
The mean PCS T-score among exposed (51.4; 95% CI: 50.6-52.1) was 2.8 T-score 
points (95% CI: −3.8 to −1.9; P < 0.001) lower than among controls (54.2; 95% CI: 
53.7-54.8). The mean MCS T-score was also 2.8 T-score points (95% CI: −3.8 to −1.9, 
P < 0.001) lower among the exposed (48.9; 95% CI: 48.2-49.6) than among the 
controls (51.7; 95% CI: 51.1-52.4). 
 “Neither condition among controls” was the reference category in regression analyses 
on an eight-level categorical variable constructed from the three dichotomous 
variables IBS (yes/no), CF (yes/no) and status as exposed or control. The reference 
category had the highest QoL for both PCS and MCS, with mean T-scores of 55.4 
(95% CI: 54.9-55.9) and 53.4 (95% CI: 52.8-54.0), respectively. The category 
“Neither condition among exposed” had the same PCS as the reference category. All 
other categories had a lower QoL than the reference categories, both for PCS and 
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MCS. The lowest PCS was found for “IBS and CF among exposed,” with a PCS of 
42.2, an estimated 13.1 T-score points lower than the reference group (95% CI for 
estimated difference: -14.8 to –11.5). The lowest MCS was found for “CF-only among 
controls,” with an MCS of 41.1, an estimated 12.3 T-score points lower than the 
reference group (95% CI for estimated difference: -14.7 to -10.0).  
We performed regression analyses with status (as exposed or control), IBS (yes/no) 
and CF (yes/no) after ten years as independent variables and PCS as the outcome. 
When adjusting for IBS and CF there was no effect of exposure on the PCS T-score, 
with an estimated difference in T-score of -0.5 (95% CI: -1.4 to 0.40; P-value: 0.28). 
We found the same for MCS, with an estimated difference in T-score of -0.75 (95% 
CI: −1.7 to 0.22; P-value: 0.13).  
We found an interaction between CF and exposure status on QoL. Exposed with CF 
had a PCS 9.2 T-score points lower than exposed without CF (95% CI for difference: -
10.7 to -7.7), whereas the corresponding number for controls was 4.7 T-score points 
lower (95% CI for difference: -6.6 to -2.7; P-value for interaction <0.001). For MCS 
we found the opposite: The reduction in MCS due to CF was larger among controls 
(estimated T-score difference -10.9; 95% CI: -12.9 to -8.9) than exposed (estimated T-
score difference -8.0; 95% CI: -9.6 to -6.4; P-value for interaction =0.027). 
There were some post-publication errors in papers 1 and 2, please see Appendix 1 





The main findings of this thesis were that acute infection with the parasite Giardia 
lamblia was associated with long-term complications and consequences such as 
perceived food intolerance after three years, IBS and CF after ten years, and a reduced 
QoL after ten years. The association between giardiasis and QoL was explained by the 
presence of IBS and CF. 
5.1 Methodological considerations 
All three sub-studies in this thesis were based on a controlled cohort study. We have 
described the design of the sub-study in paper 1 as a historical cohort study, and 
papers 2 and 3 as prospective studies. The classification of observational studies as 
prospective or historical (or retrospective) is not necessarily straight forward or even 
agreed upon in the scientific community. Based on an interesting discussion of the 
terms by Klebanoff et al (113), the sub-studies included in this thesis may be termed 
ambidirectional (meaning that they are both historical and prospective), and the 
prospective elements are more dominating the more follow-ups that are included in the 
given study.  
5.1.1 The lack of baseline data 
This was an observational study, with the cohorts established after the outbreak. We 
therefore did not have information about the respondents from before the outbreak. 
This includes a lack of information on all of the variables in the study (except for sex 
and age), including the outcome variables, which is a drawback when assessing the 
different causal roles of the various variables. We still believe that this design gives 
reliable and valid data with trustworthy results. Two designs would theoretically be 
more robust but were not applicable: 1) An observational study assessing all the 
inhabitants in an area at a randomly assigned "baseline" and then waiting to see if an 
outbreak of interest occurs. This would be both expensive and probably unethical and 
might never give results. 2) A proper randomized controlled trial emulating an 
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outbreak would also, of course, be wildly unethical. Consequently, the current design 
is the best available in the real world. 
 
It would also be possible to use the respondents' social security number and assess 
retrospective pre-outbreak data from the national database for reimbursement claims 
(which includes doctor- and patient identification-number, date and time for the 
contact, and diagnoses for the contact). One such study has been planned by members 
of the research group and may shed some light on the respondents’ pre-outbreak 
vulnerabilities. However, this strategy has methodological constraints as well.  
5.1.2 Selection bias 
Selection bias refers to bias introduced by factors influencing study participation and 
how the subjects are selected (114). The exposed in our studies are selected compared 
to all Giardia exposed in the population, in terms of help-seeking behaviour, which 
resulted in a test for Giardia lamblia cysts in their stools. If people with pre-existing 
IBS or CF would be more prone to seek medical help for acute giardiasis, we have a 
situation where our results would be biased away from the null-hypothesis of no 
association between exposure and the outcomes (IBS and CF). One could also 
speculate, however, that people with pre-existing IBS would be less inclined to seek 
medical help during giardiasis, as they could interpret their symptoms as a worsening 
of their known condition. This would bias our results towards the null. The sum of 
these and other selection biases are unknown. A few studies have examined this 
question. A study from Italy hypothesised based on their findings that rather than 
giardiasis causing IBS, it makes pre-existing IBS evident by making the symptoms 
apparent (115). This was a small study, so the results should be treated with caution. 
Parry et al found that pre-existing IBS was more frequent among cases presenting with 
gastroenteritis than among a group of controls. A study by Wensaas et al (102) from 
the Bergen Giardia outbreak included a question on whether the respondents had 
abdominal complaints at present that were absent before the outbreak, but answers to 
this question correlated poorly with information from medical records in another study 
by the same authors (116). In sum, some studies from this outbreak have assessed the 
association between pre-existing abdominal complaints and post-infectious 
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complaints, and although there were some indications of such an association (26,116), 
only a subset of patients were investigated. The question used to detect pre-outbreak 
abdominal complaints was unvalidated and prone to recall bias, and we conclude that 
the evidence for an association between pre-existing abdominal complaints and post-
infectious complaints is not clear. Even if people with pre-existing abdominal 
complaints were more likely to consult a doctor during gastroenteritis, this is not likely 
to explain all of the effect of exposure on the outcome of IBS but would overestimate 
the effect somewhat.   
 
Attrition bias is a form of selection bias due to loss of participants, both from 
nonresponse and drop-out. The response rates at our follow-ups are low but acceptable 
among the exposed (66-50%) and somewhat low among controls (36-30%). If the 
reasons for nonresponse are related to the outcome, bias can occur. We therefore 
conducted various analyses in paper 2 trying to assess selection bias (supplementary 
material in paper 2). We found that there was an association between having IBS 
among the exposed at follow-ups three and six years after the outbreak, and 
responding after ten years, but the effect was small. There was also a negative 
association between having CF after three years among controls and answering after 
ten years. These results could imply that the results at ten years were biased away from 
the null hypothesis because of nonresponse. We therefore conducted a sensitivity 
analysis where we assumed that all nonresponders among the exposed would be 
categorized as no IBS, and nonresponders in the control group would have the same 
IBS prevalence as responders. Even in this unlikely scenario, we found a positive 
association between giardiasis and IBS ten years later, and the same was also true for 
CF. We therefore conclude that the associations between exposure to Giardia and IBS 
and CF are both robust. The prevalence of IBS in the control group at the three follow-
ups reported in paper 2 ranged from 12-14%, comparable to a population survey in 
Denmark of persons aged 18-50 utilizing the Rome III criteria, which found a 
prevalence of 16% (117). This could suggest that selection bias did not influence the 
prevalence much and further supports our results.  
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5.1.3 Choosing the appropriate statistical method 
Sometimes the choice of method can have profound effects on the effect measure. We 
used chi square statistics from cross-tabulations and standard logistic regression, as 
well as generalised estimating equations and mixed models (special forms of 
regression analyses that account for matching of respondents and repeated measures). 
One could argue that we should have used a method that accounted for the matching in 
all analyses, and that we should have used only one of those. Table 4 shows that at 
least for the main outcomes of paper 2, the choice of method had a very small effect 
on the results. We also performed analyses with both generalised estimating equations 
and mixed models for some of the outcomes in paper 3, without significant changes of 
the results (data not shown). 
 
5.2 Interpretation 
In the studies comprising this thesis we found that Giardia lamblia infection was 
associated with several long-term complications and consequences. We found an 
association between exposure and perceived food intolerance three years later, 
exposure and IBS/CF ten years later, and a reduced quality of life ten years later.   
5.2.1 Giardiasis as a cause of the associated complications 
There are no universal and objective criteria to identify a certain cause- and effect 
relationship. Causality is normally referred to as more or less probable, and definitive 
proof is impossible in empirical science, although our best tentative working models 
can have practical applications (114). In 1965, Sir Bradford Hill proposed a set of nine 
  
Table 4 Unadjusted odds ratios for irritable bowel syndrome and chronic fatigue ten years after a 
2004 Giardia outbreak in Bergen, Norway, utilizing different statistical methods   
 Irritable bowel syndrome 
 
Chronic fatigue 
Statistical method  OR 95% CI 
 
OR 95% CI 
Pearson’s chi square exact 2-sided  4.75 3.62 to 6.25 
 
2.99 2.20 to 4.05 
Standard logistic regression  4.75 3.62 to 6.25 
 
2.99 2.20 to 4.05 
Generalised estimating equationsa  4.77 3.65 to 6.25 
 
3.00 2.21 to 4.06 
Mixed modelsa  4.78 3.65 to 6.25 
 
3.02 2.23 to 4.09 




considerations he argued could be useful in identifying causal associations. These 
considerations were strength, consistency, specificity, temporality, biologic gradient, 
plausibility, coherence, experimental evidence and analogy. Except for the necessity 
of the cause to precede the effect (temporality), none of them are sufficient or 
necessary in themselves to propose causality. Also, the development of more 
sophisticated methods in research and integrations of these methods has altered the 
way we use and interpret these considerations (118). Yet, they are still relevant, and 
perhaps especially so for our rather classical epidemiologic design. The following 
section will consider our findings in light of the Bradford Hill causal considerations, 
with the main attention on IBS.  
Considering the strength of an association is not necessarily straight forward. Also, a 
causal relationship can exist even if the association is weak, and a strong association 
can be a result of confounding (114). The association between exposure and the main 
outcomes of IBS and CF after ten years should be considered strong, based on 
relatively large ORs, low p-value and confounding for measured variables adjusted for 
when appropriate. The association between perceived food intolerance and exposure is 
somewhat lower in terms of the size of the OR, but not weak. It should be noted that a 
mere eyeballing of the size of ORs should be done with knowledge that arbitrary 
factors (like the number of explanatory variables in the model) other than the strength 
of the relationship per se influences its magnitude (119). The association between 
exposure and QoL is strong in terms of statistical significance, but the difference of 
2.8 T-score points between the exposed and controls for both PCS and MCS might not 
be clinically significant. Regarding IBS, our findings are consistent with findings from 
other studies, that an association between Giardia lamblia and IBS exists (120–122), 
and also between gastroenteritis caused by various agents (protozoa, bacteria, viruses) 
and IBS (123–128).  
I have previously discussed how the lack of baseline data is a concern for our study. 
This is also a threat to the issue of temporality. We know that Giardia lamblia 
infection preceded our assessments of the prevalence of IBS at the follow-ups, but we 
did not have access to the cohorts’ prevalence of IBS prior to the outbreak. However, 
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the most important issue to consider regarding temporality is whether the putative 
cause cannot (under any circumstance) precede the effect (114), which is not the case 
in our study.  
Although the prevalence of IBS after this outbreak is surprisingly high compared to 
other studies on post-infectious IBS (126), the findings are still plausible, based on 
prior knowledge from the field. Also, we have not found any research in direct conflict 
with our findings, which supports the coherence criterion. 
Qin et al systematically reviewed the evidence from animal models of post-infectious 
IBS and found that PI-IBS could be experimentally induced in rats and mice by 
infecting them with various bacteria and parasites (129). None of the reviewed articles 
included Giardia lamblia as an agent, but this nevertheless constitutes experimental 
evidence that infective gastroenteritis can cause IBS. By use of analogy, it is plausible 
that animal models with Giardia lamblia would yield similar results.  
The only causal considerations clearly not met or readily assessed by our studies are 
specificity (IBS and CF can have many causes, and Giardia infection can lead to 
various complications), and biologic gradient (we did not assess the “dose” of Giardia 
infection for the exposed cohort in any way).  
A consideration not directly related to the Bradford Hill criteria but still relevant for 
assessing causality concerns the results in paper 2. We found that the prevalence of 
IBS and CF was unchanged through all follow-ups in the control group. In the exposed 
group, the prevalence of IBS falls from three to six years and then plateaus, whereas 
the prevalence of CF falls at all three follow-ups. This indicates that the Giardia 
infection was something that happened in the lives of the exposed, that at least 
changed the trajectories of those two conditions.  
5.2.2 Our main findings in relation to the literature 
5.2.2.1 Paper 1 
Our main finding of an association between exposure to Giardia and perceived food 
intolerance long after eradication of the parasite has to the best of my knowledge not 
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been thoroughly explored previously and is a novel one. When stratifying according to 
IBS status, there was no association between giardiasis and perceived food intolerance 
in the IBS-group. In the no IBS group, there was a weak association between 
giardiasis and perceived food intolerance. The Breslow-Day test for interaction was, 
however, negative. One implication of this finding could be that IBS was a mediator 
for the relationship between giardiasis and food intolerance. However, we did not 
perform further analyses to elucidate this relationship. Also, IBS and perceived food 
intolerance was measured at the same time, so the relationship could also be the 
opposite: perceived food intolerance could be a mediator for the relationship between 
giardiasis and IBS. Alternatively, IBS and perceived food intolerance are both in part 
effects of giardiasis and developed concomitantly. It is safe to conclude that there is a 
strong relationship between IBS and perceived food intolerance, a finding in line with 
the existing literature (83,106,107,130).  
Nutrition intake is very difficult to measure accurately in questionnaires (131). 
Predefined checklists of foods probably overestimate the prevalence of those particular 
foods (132). Similarly, there are methodological issues related to the categorization 
and analysis of responses to an open-ended question. There is always a risk of 
misclassification. In this study, every category was accounted for in a codebook. The 
codebook was also checked by a nutritionist. Ideally, the classification should have 
been done by two investigators independently and checked for concordance, but we 
did not have the resources for this. If a respondent did not mention a foodstuff for a 
given category, this was coded as a “no” for that particular category. There is 
uncertainty related to the validity of this, but also, this was the only meaningful way to 
make categories available for comparisons between the two study groups. The 
probability of misclassification should be similar among the exposed and the controls, 
and hence is a non-differential misclassification. This further means that the 
misclassification will result in inferences about prevalence more uncertain than the 
inferences about associations between the exposure and the outcome. 
Like many other studies on IBS and perceived food intolerance (107,130,133), 
respondents in this study mentioned a wide range of foods as causing abdominal 
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complaints. Interestingly, only 11 participants answered "gluten" as an offending food 
(although 227 answered "cereals," many of which might contain gluten). With the 
recent focus on gluten in the media and the medical/research community, also in 
persons without celiac disease, these numbers would probably be higher if our survey 
was performed today. Based on the inherent problems with findings from 
observational studies on nutrition, our data do not justify a conclusion that these are 
the only offending foods, or even that they necessarily are the real culprits. Neither do 
our results warrant the formulation of concrete dietary advice. We conclude that food 
in general is an important issue for respondents with IBS and that the spectre of 
possible offending foods is broad. Since the publication of paper 1 there have been 
some more randomized controlled trials investigating the efficacy of the low 
FODMAP-diet in relieving symptoms among patients with IBS. In a review by 
Altobelli et al, the low-FODMAP diet was found to be superior to standard dietary 
advice. There is still a need for high quality clinical diet intervention studies for IBS in 
primary care.   
5.2.2.2 Paper 2 
Our main finding from this study was a high prevalence of IBS and CF among the 
Giardia exposed and a strong association between giardiasis and IBS/CF ten years 
after the acute infection. Persistence of IBS and CF (as measured by IBS or CF at all 
three follow-ups) was strongly associated with giardiasis. The stability among 
respondents (both in the exposed and the control group) of IBS/CF was low through 
the three follow-ups, as was the stability of the IBS-subtype.  
The still high prevalence of IBS at 43% (compared to 7-36% for PI-IBS after 
epidemics in one review (126)) found after ten years in our exposed cohort has several 
possible explanations. Selection bias has been discussed previously, and even in a 
worst-case scenario (accounting for maximum selection bias) the prevalence in our 
cohort would be rather high. Direct comparison of prevalence with other studies is 
complicated by how IBS is defined. In the above-mentioned review all the studies 
reviewed had utilized Rome I or II criteria, while Rome III was used in our study. The 
Rome III criteria had recently been published when the first survey for the cohort used 
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in this thesis was being planned. Before this, and for some time after, studies in 
Norway and worldwide often utilized the Rome II criteria, and in 2016 the Rome IV 
criteria were published (69). Hence, the amount of studies available for direct 
comparison using the same criteria are scarce, both on IBS in general, and especially 
concerning PI-IBS. A review from 2011 by Schwille-Kiuntke on post-infectious IBS 
found no studies using the Rome III criteria (126), and a later systematic review of 
post-infectious IBS after traveller’s diarrhoea found two studies using these criteria 
(124). Andresen et al followed a cohort of patients suffering from a severe infection 
with Shiga-like toxin-producing Escherichia coli (128) in 2011 and utilized the Rome 
III criteria. They found that the prevalence of IBS increased from 9.8% before the 
infection, to 25.3% 12 months after. 
The population under study might also affect the prevalence. The exposed in our 
cohort were recruited by the fact that they had consulted a doctor for abdominal 
complaints. The doctor sent stool samples to the laboratory, that later turned out to be 
positive for Giardia lamblia. The infection struck the citizens of Bergen in a random 
manner, and apart from the unknown importance of health-care seeking behaviour in 
this group. Interestingly, the reported prevalence of PI-IBS after travellers’ diarrhoea 
is lower than that after epidemics. The authors of a meta-analysis on PI-IBS after 
travellers’ diarrhoea (124) discussed the possibilities that 1) travellers are younger and 
perhaps more resilient than the average epidemic-stricken population and 2) 
respondents after a large outbreak might interact in ways that lead to over-reporting of 
symptoms. There might also be legal/financial implications of the reporting of 
symptoms after an outbreak caused by contaminated drinking water. In the 2004 
Bergen outbreak, the Municipality of Bergen assumed responsibility for the outbreak 
in 2005 and gave compensation for economic losses of the affected. Hence, such 
considerations might play a minor role for the responses three, six or even ten years 
after the outbreak.  
Several agents have been implicated in PI-IBS (23) including bacteria: Campylobacter 
jejuni, Salmonella enterica, Shigella sonnei, Escherichia coli, Clostridium difficile 
(134); viruses: Norovirus; and parasites: Giardia lamblia. A recent study found that 
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the parasite Cryptosporidium hominis was associated with diarrhoea and abdominal 
pain (PI-IBS was not an outcome) as well as fatigue (among other symptoms) up to 
two years after the infection (135). The prevalence and persistence of PI-IBS vary 
according to the agent. Bacteria have been associated with longer-lasting PI-IBS than 
viruses (23), and our research indicates that Giardia lamblia might be associated with 
longer-lasting symptoms and a stronger association to PI-IBS than bacteria.  
5.2.2.3 Paper 3 
The main findings in this study was a lower QoL among Giardia lamblia exposed 
persons ten years after the infection, as compared to a control group. The effect of the 
exposure was mediated by IBS and CF.  
Both the PCS and MCS were 2.8 T-score points lower among the exposed than among 
controls. These differences were both statistically significant at the P < 0.001 level. 
They were, however, slightly lower than the threshold for clinically significant 
differences according to the cut-off for a "minimally important difference" (MID) 
between groups of 3 T-score points (approximately 1/3 of the SD (10) from the 2009 
US population norm) (99). MID pertains to the smallest difference in score between 
groups that has some clinically meaningful effect perceivable to the individual. A 
reduction in PCS score of 3 T-score points was associated with an increased risk of 
being unable to work, losing one's job or being hospitalized the following year. A 
reduction in MCS of 3 T-score points was associated with a 40% increased risk of 
depression (99). The difference between the exposed and controls in our paper for PCS 
and MCS is close to this threshold, and even though it is not within the MID, it would 
be false to assume that this translates to no meaningful loss of QoL for any of the 
respondents. At least for PCS, a threshold of 2 T-score points for the MID has been 
discussed, and there is an inherent uncertainty in defining cut-off for any scale 
measure, especially perhaps, for a PROM-measure.  
We used a calculated 1/3 of the SD from the Norwegian population to estimate the 
upper and lower bounds of a MID, which because of SDs smaller than 10 for the 
means, yielded MIDs smaller than 3. The choice of a MID of 3 T-score points might 
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have been more correct and simpler to present, but this minor difference would not 
have altered the inferences presented below. Both the exposed and controls had a PCS 
and an MCS that was within or above that of a Norwegian population measured in an 
SF-12 1998 European validation study (98). When stratifying the respondents to the 
eight-level variable (exposure status x IBS x CF), only two out of eight groups had a 
PCS T-score lower than 1/3 of an SD of the mean from the Norwegian comparison 
population. These groups were "CF only among exposed" and "IBS and CF among 
exposed." For MCS, four out of eight groups had such a low T-score, and these were 
"CF only among exposed," "CF only among controls," "IBS and CF among exposed" 
and "IBS and CF among controls."  
We used the recommended scoring-algorithm for the SF-12v2, automated by computer 
software. Our scores were calculated using the 2009 US norms as a reference. 
Although not a primary aim of the study, we compared the findings in our study to a 
Norwegian norm that was based on the SF-12 (not v2) in a population from 1998. The 
SF12v2 scoring manual states that although the SF12-v2 is an improvement over the 
SF-12, scores from studies utilizing the SF-12v2 are comparable to the scores from 
utilizing the SF-12, and from studies utilizing SF36. Comparability is increased if the 
studies have used the standard scoring algorithm, as we did.  
Comparing our results to the Norwegian norm and to other studies utilizing the Short-
form, was done by mere eyeballing, without statistical analysis. Comparing our results 
to others was not a main objective of the study, and a subjective assessment was 
considered accurate enough to place our findings in a broader context. Even though 
the various versions of the Short-form are comparable across studies, the population 
under study will vary, and thus the differences in QoL between studies is not 
necessarily caused by the impact of the different conditions measured alone.   
How the relationship between the exposure and QoL was affected by IBS and CF was 
a secondary aim of paper 3. Inferences about causality between IBS/CF and QoL, 
about interactions between exposure and IBS/CF on QoL and about IBS and CF as 
mediators for the effects of exposure on QoL are made problematic by the fact that 
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IBS, CF and QoL were measured at the same time, after ten years. We therefore 
included analyses on IBS and CF after three and six years and the relationship with 
exposure and QoL as well. The results from these analyses were largely similar to the 
main findings, with a few exceptions. The most notable exception was the fact that the 
interesting interaction between exposure and CF on QoL was only found for CF 
measured after ten years. This could be a power problem, as there were fewer cases 
who answered both at three and ten years or six and ten years than at ten years 
independently. However, there is also a chance that this was a spurious finding.  
We used a classic approach to mediation analysis, where we compared two regression 
models, one with and one without adjusting for the mediators IBS and CF. Richiardi et 
al (136) have pointed out that under certain circumstances, this method can introduce 
bias. One circumstance is when mediator-outcome confounding exists. We did not find 
such confounding by the demographic variables assessed (marital status, level of 
education and source of income) on the mediation. Another situation is when there is 
an exposure-mediator interaction. We found an interaction between exposure and CF 
(one of the mediators) on both PCS and MCS, and this may be a source of bias in the 
mediation analysis. Methods to estimate effect of the mediation in the presence of 
exposure-mediator interaction exist (136), but we did not apply these. The final 
circumstance in which the classical approach to mediator analyses can introduce bias, 
is when the mediator-outcome confounding might be affected by the exposure. We 
discussed this briefly in paper 3. The demographic variables mentioned above are 
measured after the exposure, and hence can be affected by it. When assessing the 
relationship between the confounders and exposure, we found that only marital status 
differed significantly between the groups. For the relationship between the 
confounders and the outcome (PCS/MCS) there was an association for all the 
confounders (data not shown). We have not used methods to adjust for this. To sum 
up, we have used a classical approach to mediation analyses, prone to bias. We used 
methods to adjust for the mediator-outcome confounding, but not for the exposure-
mediator interaction nor for the situation where the mediator-outcome might be 
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affected by the exposure. Regarding the latter two, we present enough information so 
that at least the avid epidemiologists will be aware of the possible biases.  
5.2.3 Mechanisms for the development of post-infectious complications 
I have argued in the above for a causative role of Giardia lamblia in the development 
of the post-infectious complications, with most of the emphasis on IBS. IBS is thought 
of as a multifactorial disease, and gastroenteritis is one of many contributing factors 
(54). Deary et al described the cognitive behavioural model of MUS in a narrative 
review (137). The model has a structure of predisposing, precipitating and 
perpetuating factors. Applying this model to our findings, Giardia lamblia is a 
precipitating factor. As mentioned before, we do not have access to baseline 
information, and hence possible predisposing factors in our cohorts are largely 
unknown. Known risk factors (that can be thought of as predisposing factors) for 
developing post-infectious IBS are female sex, younger age and premorbid 
psychological conditions (54). Wensaas et al concluded that sex was not a strong risk 
factor for IBS after giardiasis in a three-year follow-up of the Bergen Giardia cohort 
(15). In the six-year follow-up by Hanevik et al, sex was a risk factor for IBS among 
controls, but not among the exposed (16). In paper 2, sex was not a risk factor for IBS 
among the exposed after ten years. Neuroticism has been associated with the 
development of IBS after bacterial gastroenteritis in other studies (138), but this was 
not replicated in a small group of patients (N=134) with giardiasis after the Bergen 
outbreak by Wensaas et al in a one-year follow-up (102). We did not assess premorbid 
psychological factors in the follow-up studies included in this thesis.  
As mentioned in the first paragraph of this thesis, studies from the Bergen Giardia 
research group have investigated alterations in the bowels both in giardiasis and in PI-
IBS as compared to various controls, and found some changes associated with both 
giardiasis and with PI-IBS. Several other studies have also investigated and found 
physiological bowel-alterations in PI-IBS (23,139). The fact that there are physiologic 
changes associated with PI-IBS does not in any way imply that psychological factors 
are unimportant as either predisposing, precipitating or perpetuating factors, as 
psychological stress also can lead to physiological changes. According to the cognitive 
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behavioural of MUS, psychological factors such as sensitization (heightened response 
to a stimulus because of a prior exposure to them), attention, attribution, beliefs and 
behaviour are important in the perpetuation of MUS illness (137). Even more thought-
provoking, Wildman et al raised the possibility that repeated measurements of fatigue 
in a Q fever outbreak cohort could cause or perpetuate some of the fatigue measured 
(140). Schwille-Kiuntke also discussed this as a possible phenomenon for the 
assessment of functional symptoms in general (124). Although not likely to explain all 
of the post-infectious complaints in our exposed cohort, similar mechanisms cannot be 
completely ruled out. 
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6. Conclusion 
Through three sub-studies based on mailed questionnaires to a Giardia lamblia 
exposed group of patients and a control group, we have found that giardiasis is 
associated with long-term complications up to ten years after the acute infection. 
Giardiasis was associated with perceived food intolerance three years later, and IBS 
and CF and reduced QoL ten years later.  
There are some important limitations addressed in this thesis. However, there is reason 
to believe that the design of the study mitigates most of the shortcomings. The 
associations between giardiasis and the outcomes are strong and the findings reliable, 
particularly for IBS and CF. 
The research presented in this thesis furthers our understanding regarding the aetiology 
of MUS diseases and might provide clinicians with helpful explanations for patients’ 
ailments. 
7. Further research 
Future research on large outbreaks should have routines for collecting as valid baseline 
information as soon as possible, to strengthen the conclusions of the studies. A 
possible research angle for new studies could be to try hindering the transition from 
the acute infectious/inflammatory phase to the phase with long-term complications.  
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Abstract
Background: Studies have shown an increased prevalence of irritable bowel syndrome (IBS) after acute
gastroenteritis. Food as a precipitating and perpetuating factor in IBS has gained recent interest, but food
intolerance following gastroenteritis is less investigated. The aims of this study were firstly, to compare perceived
food intolerance in a group previously exposed to Giardia lamblia with a control group; secondly, to explore the
relation with IBS status; and thirdly, to investigate associations with content of fermentable oligosaccharides,
disaccharides, monosaccharides and polyols (FODMAP) in foods reported.
Methods: This is a historical cohort study with mailed questionnaire to 1252 Giardia exposed and a control cohort
matched by gender and age. Differences between groups were investigated using bivariate and multivariate
analyses.
Results: The questionnaire response rate in the exposed group was 65.3 % (817/1252) and in the control group
31.4 % (1128/3598). The adjusted odds ratio (OR) for perceived food intolerance for the exposed group was 2.00
with 95 % confidence interval (CI): 1.65 to 2.42, as compared with the control group. Perceived intolerance for dairy
products was the most frequently reported intolerance, with an adjusted OR for the exposed of 1.95 (95 % CI: 1.51
to 2.51). Perceived intolerance for fatty foods, vegetables, fruit, cereals and alcohol was also significantly higher
in the exposed group. The groups did not differ in perceived intolerance to spicy foods, coffee or soda. The
association between exposure to Giardia infection and perceived food intolerance differed between the IBS
group and the no-IBS group, but IBS was not a significant effect modifier for the association. Perceived
intolerance for high FODMAP foods (adjusted OR 1.91) and low FODMAP foods (adjusted OR 1.55) was
significantly associated with exposure status.
Conclusion: Exposure to Giardia infection was associated with perceived food intolerance 3 years after giardiasis.
IBS status did not alter the association between exposure status and perceived food intolerance. Perceived
intolerance to high FODMAP foods and low FODMAP foods were both statistically significantly associated with
exposure to Giardia infection.
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Background
Gastroenteritis is a common condition around the globe,
both sporadic cases and in larger outbreaks caused by
contamination of drinking water or food. Post-infectious
irritable bowel syndrome (PI-IBS) as a concept has been
known for decades. Studies on patients with enteric in-
fections have shown that 4–31 % develop PI-IBS [1].
Irritable bowel syndrome (IBS) has been described fol-
lowing infections caused by bacteria [1] (Salmonella, E.
coli, Shigella, Campylobacter), virus [2] (norovirus) and
parasites [3, 4] (Giardia lamblia). The mechanisms
underlying the development of the disease are incom-
pletely understood, and treatment options are currently
the same as for sporadic irritable bowel syndrome [5].
Irritable bowel syndrome (IBS) is characterized by ab-
dominal pain and/or discomfort related to alterations in
bowel habits. It is a highly prevalent condition, and one
recent meta-study found the pooled prevalence to be
11.2 % globally, varying according to country and the
diagnostic criteria used [6]. It places a heavy burden on
both the patient and the society, as measured by quality
of life, use of health care resources, and work productiv-
ity [7]. The pathophysiologic mechanisms of the disease
are yet to be fully understood. Current hypotheses in-
clude altered gastrointestinal motility [8], brain-gut-
interactions [9] and visceral hypersensitivity [8]. There is
a possible role of inflammation, post-infectious low-
grade inflammation, genetic and immunologic factors,
enteroendocrine cells and altered microbiota, but the re-
sults are inconsistent [9]. Patients with IBS often report
that certain foods may trigger symptoms, and studies
offer some support for this [10, 11]. Perceived food in-
tolerance as a long-term complication after gastrointes-
tinal infections is less investigated.
Effective treatment options for IBS are scarce. A diet-
ary approach that has gained increased interest recently
is the low FODMAP-diet. Fermentable oligosaccharides,
disaccharides, monosaccharides and polyols (FODMAP)
are a group of carbohydrates and sugar alcohols that
share three functional properties: They are poorly
absorbed in the small intestine, they are osmotically ac-
tive molecules because of their small size, and they are
rapidly fermented by bacteria [12]. Because of these
characteristics there is a possibility that they may worsen
symptoms in IBS patients, particularly in the presence of
visceral hypersensitivity. Studies have shown that IBS pa-
tients may benefit from a diet low in FODMAP [13–17],
but there has been some critique of the methodology in
these studies, including the fact that no studies have
been conducted on unselected patients from primary
care [18]. There is a need for studies that elaborate the
role of diet in IBS.
In the autumn of 2004 there was a large outbreak of
giardiasis in the city of Bergen on the western coast of
Norway. In a controlled follow-up study with nearly
2,000 participants in 2007 it was found that the group
subject to Giardia infection 3 years prior had a signifi-
cantly higher prevalence of IBS (46 %) than the control
group (14 %) [4].
The aims of the current study were firstly, to compare
the prevalence of perceived food intolerance in the two
groups; secondly, to explore how this was related to the
IBS status in the two groups; and thirdly, to investigate
any associations with FODMAP content.
Methods
Participants
During the outbreak of giardiasis in Bergen in 2004,
1252 patients who had infection verified by detection of
Giardia lamblia in their stools were included and com-
prised the Giardia exposed group. A 2:1 matched con-
trol cohort was established by sampling two people of
the same age and gender for each exposed patient from
the entire population of Bergen. Four controls were ex-
cluded due to giardiasis during the outbreak, as self-
reported in the study questionnaire. The questionnaires
were sent by mail in October 2007, and again one month
later to non-respondents. Because of a low response rate
in the primary control group, the questionnaire was
mailed to an additional 1094 controls in May 2008. De-
tails about the study population have been published
previously [4].
Variables
The primary outcome in this report is the respondents’
self-reported reactions to food, hereafter referred to as
perceived food intolerance in line with previous litera-
ture [11, 19]. All respondents were asked the following
question (Question A): “Do certain types of food give
you abdominal symptoms?” Possible answers were:
None, light, moderate and severe. For some analyses,
these answers were further dichotomized into none vs.
light, moderate or severe. Question A was followed by
an open-ended question (Question B): “If you react (to
food), to what kind is that?” For respondents who an-
swered “no symptoms” or had a missing answer to
Question A but still gave an affirmative response about
specific types of food causing symptoms, the response
was reclassified as “light”. The unmodified “light” cat-
egory included 582 respondents, whereas the modified
one included 606.
The responses to Question B were categorized in ac-
cordance with categories used in previous studies on IBS
and food intolerance [10, 11, 19, 20], and are hereafter
referred to as food categories. A selection of these food
categories was further analysed. Reported foods were
also categorized based on assumed content of FODMAP
(high or low), hereafter referred to as high FODMAP
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foods and low FODMAP foods. FODMAP content of
the foods reported was assessed using a mobile app de-
veloped by a research team at the Department of Gastro-
enterology, Central Clinical School, Monash University,
Melbourne, Victoria, Australia. This reference tool was
developed on the basis of results from food quantifica-
tion studies [21–23]. The coding was also discussed be-
tween the first author and the clinical dietician in the
research team (GK). A total of 971 respondents an-
swered Question B. Responses that were coded as high
FODMAP foods include vegetable, cakes, wheat, milk,
apple, pear, prunes, dried fruit, and onions. Examples of
responses coded as low FODMAP foods were sugar,
cocoa, oil, rice, berries, strawberry, alcohol, soda, and
banana. Foods where assumed FODMAP content could
not be decided were categorized as “uncertain FOD-
MAP.” This category was not further analysed. High
FODMAP foods were classified according to what sub-
group of FODMAP (oligosaccharides, fructose, polyols
or lactose) they might contain. Details concerning the
coding of the variables were accounted for in a code-
book (available upon request).
Exposure in our study was defined as laboratory con-
firmed Giardia lamblia infection in 2004.
In the current study we wanted to investigate if there
was an effect modification by IBS on the association be-
tween Giardia exposure and perceived food intoler-
ance. IBS was defined according to the Rome III
criteria. A detailed description of this part of the ques-
tionnaire and the translation procedure has previously
been published [4].
Demographic information obtained was age (recorded
as a continuous variable, categorized to 20-year groups)
gender, marital status (four categories), level of educa-
tion (three categories), main occupation (originally
eight categories, reduced to four in the analyses) and
status as a student or not in the autumn of 2004. Mean
age was calculated before age was categorized to 20-
year groups.
Statistical analyses
Pearson’s chi square test (exact) was performed on differ-
ences between proportions. Results are reported as per-
centages with p-values for differences, or as unadjusted
and adjusted odds ratios (OR) with 95 % confidence inter-
vals (CI). Confounding and effect modification were evalu-
ated with logistic regression modelling, and in stratified
crosstabs with Breslow-Day test. Confounders evaluated
were status as student or not in 2004, age, gender, work,
income and level of education. All analyses of the primary
outcomes were adjusted for gender and age. Effect modifi-
cation by IBS on the association between exposure and
perceived food intolerance was investigated by stratified
cross tabulation and Breslow-Day test.
All tests were two-sided. The level of significance was
0.05. The data was analysed using the statistical software
SPSS version 22.
Ethical approval
This study has been approved by the Regional Commit-
tee for Medical and Health Research Ethics (project
150.07) and by the Ombudsman for Privacy in Research,
Norwegian Social Science Data Services (project 17014).
Respondents were informed that by completing and sub-
mitting the questionnaire, they consented to participate
in the study.
Results
The questionnaire response rate was 65.3 % (817/1252)
among the Giardia exposed and 31.4 % (1128/3598)
among controls, giving a total response rate of 40.1 %
(1945/4850). Respondents were older than non-
respondents (mean age 36.1 vs. 32.9 years, p < 0.001).
There also were a higher proportion of females among
respondents (65.7 % vs. 55.8 %, p < 0.001), as previously
reported [4, 24]. Out of 1945 participants in total, 1875
(96.4 %) could be classified as having IBS or not. As ex-
pected from the matched design, the two groups did not
differ with respect to gender and age. Further character-
istics of respondents in the exposed and the control
group are shown in Table 1.
Question A (if, and to what degree, food was perceived
to cause abdominal symptoms) was answered by 95.8 %
of the respondents (1864/1945). An additional 19 cases
were missing from the combined analyses on IBS status
and symptoms (Table 2). Among Giardia exposed
63.9 % reported perceived food intolerance as compared
to 47.6 % in the control group, giving an adjusted odds
ratio of 2.00 (95 % CI: 1.65 to 2.42). When stratifying ac-
cording to IBS status, there were no significant differ-
ences between the exposed and controls in the IBS-
group regarding perceived food intolerance. Within the
no-IBS group the prevalence of perceived food intoler-
ance was higher among the exposed (49 %) than the
controls (42.3 %) (adjusted OR: 1.36, 95 % CI: 1.07 to
1.72). However, the Breslow-Day test for effect modifica-
tion was negative, meaning that the difference in odds
ratio between the IBS and the no-IBS group was not sta-
tistically significant.
Question B (types of food perceived to cause symp-
toms) was answered by 49.9 % (971/1945) (Table 3).
Dairy products was the most frequently reported food
category, and was reported significantly more often in
the exposed group than among controls with an adjusted
OR of 1.95 (95 % CI: 1.51 to 2.51). Food categories cre-
ated based on the responses were (in order of descend-
ing frequency given for the total study population in
parentheses): Dairy products (292), spicy foods (256),
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vegetables (232), cereals (227), milk (163), fruit (120), al-
cohol (109), meats (93), coffee (91), fatty foods (75),
wheat (73), unclassified (46), sweets (45), soda (40),
sugar (33), dinners (29), gravy/dressing (28), beer (26),
chocolate (25), juice (25), eggs (23), baked goods (22),
fish (21), shellfish (21), yeast products (18), smoked food
(17), nuts (17), processed food (15), tomato/tomato
products (15), fruit juice (14), gluten (11), fibre (8), tea
(8), salted food (8), soy (3).
Perceived intolerance to high FODMAP foods was re-
ported more often in the exposed group compared to
the control group with an adjusted OR of 1.91 (95 % CI:
1.57 to 2.33), as was intolerance to low FODMAP foods,
with an adjusted OR of 1.55 (95 % CI: 1.26 to 1.92). A
total of 585 respondents reported intolerance to high
FODMAP foods, 461 reported intolerance to low FOD-
MAP foods, and 528 respondents reported intolerance
to foods where FODMAP content could not be ascer-
tained. The ORs for high FODMAP foods were some-
what larger than the ORs for low FODMAP foods
(Tables 3 and 4). Since these categories were not mutu-
ally exclusive, there was no direct way to test the poten-
tial differences in strength between these associations
statistically.
Perceived food intolerance for specific food categories
in the two study groups (Giardia group vs. control
group) was further analysed according to IBS status.
Among respondents with IBS, the Giardia group re-
ported vegetables, fruit, alcohol and the FODMAP sub-
group polyols significantly more often than did controls.
Among respondents without IBS, dairy products, fatty
foods, vegetables, fruit, high FODMAP, and the FOD-
MAP subgroups lactose, polyols and fructose were re-
ported significantly more frequently by the Giardia
exposed group than by controls (Table 4). The test for
effect modification by IBS on perceived food intolerance
was negative for these data.
We also investigated the difference in perceived food
intolerance for the specific food categories between re-
spondents with IBS compared to respondents without
IBS when stratified according to exposure status. Within
the exposed stratum respondents with IBS had statisti-
cally significantly more perceived intolerance for the
food categories dairy products, spicy foods, fatty foods,
vegetables, fruit, cereals and alcohol. Within the control
stratum respondents with IBS had statistically signifi-
cantly more perceived intolerance for the same food cat-
egories as mentioned above except for spicy foods,
vegetables and alcohol (Additional file 1: Table S1).
Sub-group analyses on cases with moderate or severe
symptoms from intake of food were of low value because
of a low number of cases. No association was found be-
tween different subtypes of IBS (diarrhoea-predominant,
obstipation-predominant, and mixed) and perceived
food intolerances (Additional file 2: Table S2).
There was a tendency towards women reporting a
higher prevalence of perceived food intolerance for
most food categories than men, but this tendency was
the same in both the exposed and the control group
(Additional file 3: Table S3).
Discussion
The main result of this study is that there was a higher
prevalence of perceived food intolerance in the exposed
group compared to a control group three years after
verified Giardia infection. IBS was not an effect modi-
fier for this association. Perceived intolerance to high
FODMAP foods and low FODMAP foods were both
Table 1 Characteristics of 817 Giardia exposed and 1128
controls in Bergen, Norway 3 years after outbreak of
Giardia-epidemic in 2004
Characteristic Exposed N = 817 Controls N = 1128 P
N % N %
Age groups, years 0.107
0–19 39 4.8 36 3.2
20–39 526 64.4 736 65.2
40–59 187 22.9 276 24.5
60–79 56 6.9 76 6.7
80–99 9 1.1 4 0.4
Females 540 66.1 738 65.4 0.772
Marital Status 0.003
Single 271 33.5 293 26.1
Married 497 61.4 778 69.3
Divorced/separated 33 4.1 41 3.7
Widow/widower 9 1.1 11 1.0
Education 0.004
Primary school 37 4.7 59 5.3
Secondary school 169 21.3 308 27.7
University 587 74.0 746 67.0
Source of income <0.001
Working 576 71.1 881 78.7
Out of Work 70 8.6 96 8.6
Student 137 16.9 121 10.8
Other 27 3.3 22 2.0
Student autumn 2004 <0.001
No 503 62.7 842 75.8
Yes, full time 261 32.5 229 20.6
Yes, part time 38 4.7 40 3.6
IBS 355 46.1 155 14.0 <0.001
Abbreviations: IBS Irritable Bowel Syndrome, P P-value from Pearson’s chi
square (exact)
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statistically significantly associated with exposure to
Giardia infection.
Limitations and strengths
Some of the limitations regarding the data used in this
study have been described before [4, 24]. The response
rate in the exposed group (65,3 %) is reasonably high,
however, selection bias cannot be ruled out. This may
impact the prevalence, but estimates of association are
more robust. The exposed group is selected on the basis
of having seen a doctor and thus having had giardiasis
diagnosed by positive stool samples. The differences in
characteristics of this group compared to those who
might have had giardiasis without seeking medical atten-
tion is not known. Unbiased baseline information about
IBS, food intolerance, previous gastrointestinal infections
or other illnesses is impossible to obtain, as this may be
regarded as a natural, unplanned experiment. However,
this problem of missing information is similar for the ex-
posed group and the control group, and most of these
factors are presumed to be equally distributed between
the two groups prior to the giardiasis outbreak.
The exposed group has had a defined gastrointestinal
illness that may lead to increased wariness of possible
causes of their abdominal complaints, including food in-
tolerance. Hence they might not actually be more sus-
ceptible to intolerance per se.
The response rate in the control group (31.4 %) is rela-
tively low and there is a risk of selection bias. The
prevalence of IBS in our control group is 14.0 %, which
is a little higher than 8.4 %, the prevalence in the general
Norwegian population as found in a large public health
survey in 2006 [25]. Our study used the Rome III cri-
teria, which have been shown in a study [26] to find a
higher prevalence of IBS than the Rome II criteria used
in the above-mentioned study. In sum, this may indicate
that our control group is not too dissimilar from the
general population. Again, the investigation of associa-
tions, with use of relative outcome measures such as
OR, depends to a lesser degree on such biases.
The questionnaire items about food have not been vali-
dated, and the reliability is not known. They do not con-
stitute a complete assessment of the respondents’ diet.
The classification of an open-ended question may be
subject to interpreter bias, and there is a potential for mis-
classification to a varying degree depending on the specific
category. All food categories and how the answers were
coded were accounted for in a codebook. Although quan-
titative analyses on qualitative data is not straight forward,
one advantage of using an open-ended question instead of
a closed-ended one is that it is unguided by any precon-
ceived theory. The respondents were free to answer
whichever type of food they perceived as giving symptoms.
Also, there were 971 responses to the open-ended ques-
tion, many of which were readily and unambiguously
coded to meaningful food categories. This study was per-
formed in 2007, before the concept of FODMAP-content
in the diet was generally known, and the responses will
Table 2 Perceived food intolerance in Giardia exposed (n = 764) and a control group (n = 1100) 3 years after an outbreak of
giardiasis in Bergen, Norway, 2004
Perceived food intolerancea
Group No Yesb Severity of perceived food intolerance
Unadjusted Adjustedc Light Moderate Severe P
N n % n % OR 95 % CI OR 95 % CI n % n % n %
Exposure status
Exposed 764 276 36.1 488 63.9 1.94 1.61 to 2.35 2.00 1.65 to 2.42 238 31.2 168 22.0 82 10.7 <0.001
Control 1100 576 52.4 524 47.6 368 33.5 116 10.5 40 3.6
IBS status
IBS 501 98 19.6 403 80.4 5.16 4.04 to 6.60 5.03 3.93 to 6.45 147 29.3 167 33.3 89 17.8 <0.001
No-IBS 1344 748 55.7 596 44.3 451 33.6 113 8.4 32 2.4
Within IBS
Exposed 348 65 18.7 283 81.3 1.20d 0.75 to 1.92 1.25 0.78 to 2.01 105 30.2 111 31.9 67 19.3 0.418
Control 153 33 21.6 120 78.4 42 27.5 56 36.6 22 14.4
Within No-IBS
Exposed 406 207 51.0 199 49.0 1.31d 1.04 to 1.66 1.36 1.07 to 1.72 130 32.0 55 13.5 14 3.4 <0.001
Control 938 541 57.7 397 42.3 321 34.2 58 6.2 18 1.9
Abbreviations: IBS irritable bowel syndrome, P p-value from Pearson’s chi square test (exact), CI confidence interval, OR odds ratio
aThe question pertaining to these categories was: “Do certain types of food give you abdominal symptoms?” with four alternatives: none, light, moderate, severe
bFour level response variable dichotomized to no (none) vs. yes (light, moderate or severe)
cAdjusted for gender and age
dThe Breslis reasonably high, howeverow-Day test was non-significant
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not be biased by the recent interest in this diet. Based on
these considerations we found that a quantitative ap-
proach was justified.
Interpretation
Perceived food intolerance in a post-infectious setting
has been scarcely investigated. Short-term lactose malab-
sorption after giardiasis has been described, but with
contradictory findings [27, 28]. Fat malabsorption with
steatorrhoea and diarrhoea can occur in chronic giardia-
sis, as can folate, B12 and vitamin A deficiency [27], but
these are usually resolved with appropriate treatment. In
our study the prevalence of perceived intolerance for
both dairy products and fatty foods is relatively high,
and significantly higher in the exposed than in the con-
trol group. Our study is not designed to investigate the
mechanisms behind perceived food intolerance.
Recent studies and reviews have elucidated some of
the mechanisms behind the development of PI-IBS after
infective gastroenteritis [1]. Similar pathophysiologic
mechanisms have also been found in sporadic IBS [9]. In
this study we find a similar pattern of perceived food in-
tolerance among Giardia exposed respondents with IBS
(predominantly PI-IBS) and controls with IBS (sporadic
IBS), but with a tendency, sometimes statistically signifi-
cant, towards the exposed more often reporting intoler-
ance for the specific food categories. Our results do not
help clarify whether PI-IBS might be the same entity as
sporadic IBS.
The prevalence of IBS and perceived food intolerance
were measured at the same time. No inferences about
causative pathways between IBS and perceived food in-
tolerance can be made. We found that the exposed had
a higher prevalence of perceived food intolerance than
controls, and it has previously been found that this
group has a higher prevalence of IBS [4]. There was also
a significantly higher prevalence of perceived food in-
tolerance among exposed in the no-IBS group. One hy-
pothesis is that giardiasis causes alterations in the
gastrointestinal tract that are important in the pathogen-
esis of both IBS and food intolerance. This does not sug-
gest that the pathogenesis is identical, but there might
be some common immunological pathways involved.
In our study 81.3 % of respondents with IBS in the ex-
posed group and 78.4 % with IBS in the control group
reported perceived food intolerance when this was
defined as light, moderate or severe food-related abdom-
inal complaints. Among respondents without IBS the
Table 3 Perceived food intolerance according to food categories and FODMAP content in 817 Giardia exposed and 1128 controls
three years after an outbreak of giardiasis in Bergen, Norway, 2004
Exposed N = 817 Controls N = 1128 Unadjusted Adjustedb
Food categoriesa n % n % ORc 95 % CI ORc 95 % CI
Food categories
Dairy products 163 20.0 129 11.4 1.93 1.50 to 2.48 1.95 1.51 to 2.51
Spicy foods 119 14.6 137 12.1 1.23 0.95 to 1.61 1.25 0.96 to 1.63
Fatty foods 48 5.9 27 2.4 2.55 1.57 to 4.12 2.63 1.62 to 4.26
Vegetables 118 14.4 114 10.1 1.50 1.14 to 1.98 1.56 1.18 to 2.06
Fruit 75 9.2 45 4.0 2.43 1.66 to 3.56 2.45 1.67 to 3.60
Cereals 128 15.7 99 8.8 1.93 1.46 to 2.55 1.98 1.49 to 2.62
Alcohol 66 8.1 43 3.8 2.22 1.49 to 3.29 2.29 1.54 to 3.40
Coffee 39 4.8 52 4.6 1.04 0.68 to 1.59 1.05 0.68 to 1.61
Soda 17 2.1 23 2.0 1.02 0.54 to 1.92 1.03 0.55 to 1.94
FODMAP Contentd
High FODMAP 308 37.7 277 24.6 1.86 1.53 to 2.26 1.91 1.57 to 2.33
Low FODMAP 230 28.2 231 20.5 1.52 1.23 to 1.88 1.55 1.26 to 1.92
FODMAP subtype
Oligosaccharides 190 23.3 187 16.6 1.53 1.22 to 1.91 1.58 1.25 to 1.99
Lactose 156 19.1 128 11.3 1.84 1.43 to 2.38 1.86 1.44 to 2.40
Polyols 78 9.5 45 4.0 2.54 1.74 to 3.71 2.57 1.76 to 3.77
Fructose 71 8.7 39 3.5 2.66 1.78 to 3.97 2.69 1.80 to 4.02
Abbreviations: FODMAP fermentable oligo-, di- and monosaccharides and polyols; IBS irritable bowel syndrome; CI confidence interval; OR Odds ratio.
aThe question pertaining to these categories was: “If you react (to food), to what kind is that?”
bAdjusted for gender and age
cStatistically significant ORs are presented in bold font
dAssumed FODMAP content of the response(s) to the open-ended question about food
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proportions were 49.0 and 42.3 %, respectively. These re-
sults were comparable to a recent dietary survey per-
formed on Irish IBS-patients (89.6 %) and a comparative
group (55.0 %) [29]. The results for the non-IBS group is
higher than what was found in a general UK population
in 1994 (20.4 %) [30]. Other studies on IBS and per-
ceived food intolerances have found prevalence ranging
from 25 to 70 % [11, 19, 31, 32]. The reasons for the
variance in prevalence of perceived food intolerance re-
ported between studies might be due to different ways of
measuring food intolerance, because of differences in
the IBS-populations under investigation (e.g. inpatient
vs. outpatient), and maybe due to a development in diet-
ary trends over time.
Milk, dairy products, wheat products, caffeine, certain
meat, certain vegetables, hot spices, alcohol, fat, fibre,
fried food and smoked products are some of the foods
stated in other studies to cause symptoms in IBS pa-
tients [10, 20]. The first nine of these food categories are
also among the quantitatively most important in all in-
vestigated groups in our study, whereas the latter three
are less frequently reported. Some of the above-
mentioned food categories (dairy products, fatty foods
and cereals) are significantly associated with IBS both in
the exposed group and the control group. There are
some similarities between the findings in our study and
other studies on IBS and diet [10, 20]. However, as the
validity and reliability of our questionnaire-items regard-
ing food have not been tested, the results must be inter-
preted with caution.
There is a general tendency that the prevalence of per-
ceived food intolerance for the various foods in our study
is lower than that in other studies [11, 19, 29]. This could
be due to the fact that most of the other studies use ques-
tionnaires with a predefined checklist of food items, which
is known to overestimate the prevalence of intolerance to
the included food items [33]. However, the prevalence of
perceived food intolerance in our study is also lower than
those reported in another study that used an open-ended
question to map food perceived to cause symptoms [29].
This could be partially explained by a stricter coding of
some of the food categories in our study, and also due to
the fact that the patients included in the study were re-
cruited from a gastroenterology clinic, and might thus be
more severely ill than our respondents, who were re-
cruited from the general population.
Table 4 Comparison of 770 Giardia exposed and 1105 controls stratified to IBS status, on perceived food intolerance according to
food categories and FODMAP content 3 years after outbreak of a Giardia-epidemic in Bergen, Norway, 2004










Food categoriesa n % n % OR 95% CI OR 95 % CI n % n % OR 95 % CI OR 95 % CI
Food Categories
Dairy products 96 27.0 38 24.5 1.14 0.74 to 1.76 1.18 0.76 to 1.84 64 15.4 90 9.5 1.74 1.24 to 2.46 1.78 1.26 to 2.53
Spicy foods 69 19.4 26 16.8 1.20 0.73 to 1.97 1.24 0.75 to 2.04 48 11.6 109 11.5 1.01 0.70 to 1.45 1.04 0.72 to 1.49
Fatty foods 31 8.7 8 5.2 1.76 0.79 to 3.92 1.79 0.80 to 4.02 16 3.9 18 1.9 2.08 1.05 to 4.11 2.19 1.10 to 4.34
Vegetables 79 22.3 24 15.5 1.56 0.95 to 2.58 1.69 1.02 to 2.81 39 9.4 89 9.4 1.00 0.68 to 1.49 1.08 0.72 to 1.60
Fruit 49 13.8 12 7.7 1.91 0.99 to 3.70 2.04 1.05 to 3.97 25 6.0 31 3.3 1.90 1.11 to 3.26 1.96 1.14 to 3.38
Cereals 91 25.6 36 23.2 1.14 0.73 to 1.77 1.21 0.77 to 1.89 36 8.7 63 6.6 1.34 0.87 to 2.05 1.41 0.91 to 2.16
Alcohol 43 12.1 8 5.2 2.53 1.16 to 5.52 2.57 1.18 to 5.61 22 5.3 34 3.6 1.51 0.87 to 2.61 1.55 0.89 to 2.69
Coffee 23 6.5 12 7.7 0.83 0.40 to 1.70 0.84 0.40 to 1.73 16 3.9 40 4.2 0.91 0.51 to 1.65 0.92 0.51 to 1.66
Soda 9 2.5 6 3.9 0.65 0.23 to 1.85 0.67 0.23 to 1.91 7 1.7 17 1.8 0.94 0.39 to 2.29 0.96 0.39 to 2.34
FODMAP Contentc
High FODMAP 186 52.4 74 47.7 1.21 0.83 to 1.76 1.27 0.87 to 1.87 116 28.0 201 21.2 1.45 1.11 to 1.88 1.51 1.15 to 1.98
Low FODMAP 145 40.8 57 36.8 1.19 0.81 to 1.75 1.22 0.83 to 1.80 83 20.0 171 18.0 1.14 0.85 to 1.53 1.17 0.88 to 1.58
FODMAP subtype
Oligosaccharides 131 36.9 51 32.9 1.19 0.80 to 1.78 1.29 0.86 to 1.94 58 14.0 135 14.2 0.98 0.70 to 1.37 1.04 0.74 to 1.46
Lactose 93 26.2 39 25.2 1.06 0.69 to 1.63 1.09 0.70 to 1.69 60 14.5 88 9.3 1.66 1.17 to 2.35 1.69 1.19 to 2.41
Polyols 51 14.4 13 8.4 1.83 0.97 to 3.48 1.91 1.01 to 3.65 25 6.0 31 3.3 1.90 1.11 to 3.26 1.95 1.14 to 3.36
Fructose 45 12.7 14 9.0 1.46 0.78 to 2.75 1.49 0.79 to 2.81 24 5.8 25 2.6 2.27 1.28 to 4.03 2.31 1.30 to 4.11
Abbreviations: FODMAP fermentable oligo-, di- and monosaccharides and polyols; IBS irritable bowel syndrome; CI confidence Interval; OR Odds ratio
aThe question pertaining to these categories was: “If you react (to food), to what kind is that?”
bAdjusted for gender and age
cAssumed FODMAP content of the response(s) to the open-ended question about food
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We found a statistically significant association between
exposure status and perceived intolerance to both high
and low FODMAP foods. Because the categories of high
and low FODMAP foods were not mutually exclusive,
the strength of the associations could not be compared
statistically, but rather the results had to be interpreted
more subjectively. The OR for high FODMAP foods was
slightly higher than that for low FODMAP foods both in
the unstratified and stratified (according to IBS-status)
analyses, but with substantial overlap of the confidence
intervals (Tables 3 and 4). The current study does not
contradict or support the findings from other studies
suggesting that high FODMAP content may add to
symptoms among vulnerable individuals.
Food intolerance in IBS should be further investigated,
especially with randomized controlled diet intervention
studies in primary health care. We would propose that
such a diet could be based on the FODMAP concept,
but also include a tailor-made diet based on the patient’s
perceived intolerances, followed by reintroduction.
Conclusion
Giardia exposed participants had a higher prevalence of
perceived food intolerance than a control group three
years after acute gastroenteritis. The association between
exposure to Giardia infection and perceived food in-
tolerance differed between the IBS group and the no-IBS
group, but IBS was not a significant effect modifier for
the association. There was a significantly higher preva-
lence of perceived intolerance to foods both high and
low in FODMAP content in the exposed group as com-
pared to the control group. Our findings did not indicate
a stronger association between Giardia exposure and
perceived intolerance to high FODMAP foods as com-
pared to low FODMAP foods.
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Prevalence of Irritable Bowel Syndrome and Chronic
Fatigue 10 Years After Giardia Infection
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BACKGROUND & AIMS: Irritable bowel syndrome (IBS) is a complication that can follow gastrointestinal infection, but
it is not clear if patients also develop chronic fatigue. We investigated the prevalence and odds
ratio of IBS and chronic fatigue 10 years after an outbreak of Giardia lamblia, compared with a
control cohort, and changes in prevalence over time.
METHODS: We performed a prospective follow-up study of 1252 laboratory-confirmed cases of giardiasis
(exposed), which developed in Bergen, Norway in 2004. Statistics Norway provided us with
information from 2504 unexposed individuals from Bergen, matched by age and sex (controls).
Questionnaires were mailed to participants 3, 6, and 10 years after the outbreak. Results from
the 3- and 6-year follow-up analyses have been published previously. We report the 10-year
data and changes in prevalence among time points, determined by logistic regression using
generalized estimating equations.
RESULTS: The prevalence of IBS 10 years after the outbreak was 43% (n [ 248) among 576 exposed
individuals and 14% (n [ 94) among 685 controls (adjusted odds ratio for development of IBS
in exposed individuals, 4.74; 95% CI, 3.61–6.23). At this time point, the prevalence of chronic
fatigue was 26% (n [ 153) among 587 exposed individuals and 11% (n [ 73) among 692
controls (adjusted odds ratio, 3.01; 95% CI, 2.22–4.08). The prevalence of IBS among exposed
persons did not change significantly from 6 years after infection (40%) to 10 years after
infection (43%; adjusted odds ratio for the change 1.03; 95% CI, 0.87–1.22). However, the
prevalence of chronic fatigue decreased from 31% at 6 years after infection to 26% at 10 years
after infection (adjusted odds ratio for the change 0.74; 95% CI, 0.61–0.90).
CONCLUSION: The prevalence of IBS did not change significantly from 6 years after an outbreak of Giardia
lamblia infection in Norway to 10 years after. However, the prevalence of chronic fatigue
decreased significantly from 6 to 10 years afterward. IBS and chronic fatigue were still asso-
ciated with giardiasis 10 years after the outbreak.
Keywords: Epidemiology; Bacteria; Microbiota; Long-Term Outcome.
Irritable bowel syndrome (IBS) is a functionalgastrointestinal disorder that constitutes a sub-
stantial economic burden to society.1 It is a common
condition, with a pooled prevalence of 11.2%.1 Chronic
fatigue (CF) is another common complaint among
patients seeking primary care, and 1 study found a
prevalence of 24% in this population.2 Despite its
potentially debilitating features, it is less investigated.
Fatigue is more commonly studied as part of the less
prevalent CF syndrome (CFS).3 IBS and CF or CFS share a
lack of consistent biologic findings and both conditions
are often categorized as functional disorders.4
Etiology for both IBS and CF is incompletely under-
stood, but both conditions have been associated with
previous infections.3,5 Postinfectious IBS (PI-IBS) has
been described following outbreaks, among travelers
returning from abroad, or as sporadic cases.5–10 The rate
of recovery from PI-IBS varies between studies, and
Abbreviations used in this paper: AFE, attributable fraction among the
exposed; aOR, adjusted odds ratio; CF, chronic fatigue; CFS, chronic
fatigue syndrome; CI, confidence interval; IBS, irritable bowel syndrome;
OR, odds ratio; PI-IBS, post-infectious irritable bowel syndrome.
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bacterial infections seem to be associated with more pro-
longed symptoms than viral infections.10 One study after
an outbreak of bacterial dysentery reported that IBS was
associated with exposure up to 8 years after the acute
infection.6 A more recent study found that IBS was asso-
ciated with shigellosis after 1 and 3 years’ postexposure
follow-up, but not after 5, 8, or 10 years.7 Postinfectious CF
as part of CFS has been reported as a complication after
various acute viral and bacterial infections.3,11–14
In the autumn of 2004, the parasite Giardia lamblia
contaminated 1 of the municipal drinking-water reser-
voirs in Bergen, likely due to broken sewage pipes. This is
one of the largest waterborne outbreaks ever recorded in
Norway,15 and 1252 patients had laboratory confirmed
giardiasis that was linked to the outbreak.9 Several post-
infectious conditions have been studied in this cohort over
time, and our research group has previously found an
association between Giardia lamblia infection and IBS and
CF both 3 and 6 years after the acute illness.8,9 The
prevalence fell from 3 to 6 years for both conditions.
The primary aim of the current study was to estimate
the prevalence and odds ratio of IBS and CF 10 years after
acute giardiasis relative to a control cohort. The secondary
aims were to investigate changes in prevalence from 3 to
10 and from 6 to 10 years and to estimate incidence,
recovery, and persistence of these conditions.
Methods
Participants
This study was a prospective follow-up of a cohort of
1252 patients (the exposed group) and a control group 3,
6, and 10 years after laboratory verified Giardia infection
during a waterborne outbreak in the autumn of 2004. On
our request, Statistics Norway established a 2:1 control
group of 2504 individuals from Bergen matched by age
and sex. There was a predominance of women in the
exposed target population (61%, 764 of 1252). Children
under 18 years of age were excluded from the data
collection at the 10-year follow-up, and hence these
children were retrospectively also excluded from all
analyses based on the data collections at the 3- and 6-
year follow-ups (Table 1). Analyses of prevalence
changes from 3 to 6 years8 have been published previ-
ously, but were calculated anew for this study. The
Regional Committee for Ethics in Medical Research
approved the study (ref. no. 2014/1372).
Variables
The primary outcome variables were IBS and CF 10
years after giardiasis in the exposed and the control
group, as well as the following subgroup categories: se-
vere IBS, severe CF, IBS, and CF combined, IBS only and
CF only. Secondary outcomes were changes in prevalence
of IBS and CF from 3 to 10 years (for IBS and CF only),
and from 6 to 10 years (all subgroup categories). Re-
spondents who had either IBS or CF at all 3 follow-ups
were defined as having a persistent condition.
IBS was defined according to the Rome III criteria,16
where respondents who had recurrent abdominal pain
or discomfort at least 3 days/month in the last 3 months
were defined as having IBS if their pain or discomfort
was also associated with 2 or more of the additional IBS
criteria. These symptoms must also have had an onset at
Table 1. Cohorts Available for Analyses 3, 6, and 10 Years After a Giardia lamblia Outbreak in Bergen, Norway, 2004
Cohort
Exposeda Control subjectsb Total
n % n % n %
Original target population 2007 1252 100 2504 100 3756 100
Children removedc 34 68 102
Target population 2007 1218 100 2436 100 3654 100
Study population 2007 802 66 843 35 1645 45
Lost to follow-upd 13 58
Target population 2010 1205 100 2378 100 3583 100
Study population 2010 731 61 852 36 1583 44
Lost to follow-upd 29 48
Target population 2015 1176 100 2330 100 3506 100
Questionnaires returned 2015 592 50 709 30 1301 37
Giardia during outbreak 6
Incomplete response 2 6
Withdrawn questionnaire 1
Nonresponders 584 1622 2206
Study population 2015 590 50 696 30 1286 37
Responded at all follow-ups 427 36 365 16 792 23
aGiardia exposed in 2004.
bSex and age matched controls from Bergen, Norway.
cChildren younger than 18 years of age in 2015 were removed from original (and subsequent) target populations.
dEmigrated, died, withdrawn, or address not found.
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least 6 months before the response. When IBS limited
daily activities at least often, we defined this as severe
IBS. We also defined the IBS subtypes according to the
Rome III criteria.16
Fatigue was defined using the validated Fatigue
Questionnaire.17 The questionnaire consists of 13 ques-
tions, with 11 questions addressing different aspects of
fatigue. The severity of fatigue was reported on a 4 item
Likert-type scale with responses ranging from 0 (less than
normal) to 3 (much more than normal). The scores were
added for a total fatigue score (range, 0–33). The scores
were also dichotomized (0 and 1 into 0, 2, and 3 into 1)
and CF was defined as a dichotomized score of 4 or more,
provided the symptoms had lasted 6 months or more.
Severe fatigue was defined as CF with a total fatigue score
of 23 or more. Cases with more than 4 missing answers on
the 11 fatigue related questions were excluded from the
analyses on CF. In cases with 4 or less missing responses
the missing values were replaced with the mean of all the
responses to that particular question.
Demographic variables recorded and evaluated as
potential confounders were sex, age, marital status,
educational level, and main occupation. Sex and age were
additionally considered as potential interacting variables
for the associations between the exposure and the
outcomes.
Nonresponders were compared with responders on
age and sex, and only included in nonresponder analyses.
Analyses and Statistical Methods
Descriptive statistics were calculated as percentage
or mean. Fisher’s exact 2-sided mid-P test in 2 ! 2 tables
was used for binary outcomes,18 and Pearson’s chi
square exact 2-sided test for associations in 2 ! k tables
was used for multilevel outcomes. Gosset’s unpaired t
test was used to compare means for continuous
variables.19
Selection bias analyses were performed and details
regarding these are available as supplementary text.
Prevalence at 10 years was compared between the
Giardia exposed and controls using odds ratio (OR) with
95% confidence interval (CI). Binary logistic regression
and cross-tabulations were used when analyzing CF and
IBS to assess risk factors. Interactions were tested by the
Breslow-Day test for homogeneity of odds ratios after
stratification.
The attributable fraction among the exposed (AFE)
was calculated as a percentage by the formula AFE % ¼
(1 – 1/RR) ! 100%.
Changes in prevalence between follow-ups were
calculated using binary logistic regression with the method
of generalized estimating equations. This method accounts
for correlation between repeated measures and the
matcheddesign. Data fromall the respondents fromall time
points were included. The results from these analyseswere
presented as age- and sex-adjusted OR (aOR).
Frequencies of incident, recovered and persistent IBS
or CF were calculated in 2 ! k tables. Associations be-
tween exposure and persisting IBS or CF were evaluated
by binary logistic regression with calculations of age and
sex aOR.
All tests were 2 sided with a level of statistical sig-
nificance set to .05. All analyses were done using IBM
SPSS Statistics for Windows, Version 24.0 (IBM Corp,
Armonk, NY). Sankey diagrams used for Figure 1 and
Supplementary Table 3 with figure were plotted using
R20 with the package sankeyD3.21
Results
The response rate at the 10-year follow-up was 50%
(592 of 1176) among the exposed, and 30% (708 of
2330) among control subjects (Table 1). Responders to
the 10-year questionnaire were older (43.3 years) than
nonresponders (41.0 years, P < .001). There were more
women among responders (857 of 1300, 66%) than
among nonresponders (1307 of 2206, 59%; P < .001).
Demographically, the exposed and the control group
differed only in marital status after 10 years (Table 2).
Results from selection bias analyses are available as
supplementary text and Supplementary Tables 1 and 2.
The prevalence of IBS 10 years after the outbreak was
43% (248 of 576) in the exposed group and 14% (94 of
685) in the control group, giving an aOR for IBS among
the Giardia exposed of 4.74 (95% CI, 3.61–6.23). The AFE
for IBS was among Giardia exposed was 68% (95% CI,
61%–74%).
The prevalence of CF was 26% (153 of 587) among
exposed and 11% (73 of 692) among controls, with an
aOR of 3.01 (95% CI, 2.22–4.08). The AFE for CF was
60% (95% CI, 48%–69%). Corresponding figures for the
subgroup outcomes are presented in Table 3.
The prevalence of IBS was 44% (169 of 388) among
women in the exposed group and 42% (79 of 188)
among men (P ¼ .79). The prevalence of IBS among
women in the control group was 16% (71 of 446) and
among men it was 10% (23 of 239, P ¼ .03). The
Breslow-Day test for interaction between exposure and
sex was negative (P ¼ .10). Sex was not a risk factor for
CF in any of the groups. Age was not a risk factor for any
of the conditions in either of the groups.
The decrease in prevalence of IBS in the exposed
cohort from 3 (47%) to 6 (40%) years (as previously
reported8) had an aOR for the change of 0.73 (95% CI,
0.62–0.86). The decrease in prevalence of IBS from 3
(47%) to 10 (43%) years in this cohort had an aOR for
the change of 0.75 (95% CI, 0.63–0.90). No change was
found from 6 to 10 years. In the control group, there
were no changes in prevalence of IBS for any time period
(Table 4).
The prevalence of CF in the exposed cohort decreased
from 3 (47%) to 6 (31%) years8 after exposure with an
aOR for the change of 0.53 (95% CI, 0.46–0.62), from 3 to
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Figure 1. The contents of Table 5 visualized as Sankey diagrams. Letters A–H in Table 5 correspond to lines A–H in the figure
graphic. The thickness of the lines corresponds to the proportion of that particular group relative to the population of 399 for
the exposed group and 356 for the control group.
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10 years (aOR for the change 0.40; 95% CI, 0.33–0.48)
and from 6 (31%) to 10 (26%) years with an aOR of 0.74
(95% CI, 0.61–0.90). In the control cohort, there were no
changes in prevalence of CF for any time period
(Table 4). No interaction was found by sex or age on the
time changes for either IBS or CF. The corresponding
figures for the subgroup outcomes are presented in
Table 4.
The main outcomes IBS and CF were dichotomous
and were measured at 3 different time points. Hence,
there were 8 possible trajectories for the subgroup of
respondents (n ¼ 755 for IBS, n ¼ 770 for CF) who
Table 2. Demographics of the Analyzed Cohorts 10 Years After a Giardia lamblia Outbreak in Bergen, Norway, 2004
Characteristics
Respondents who answered at
10-year follow-up
n ¼ 1286






n ¼ 590 %a n ¼ 696 %a n ¼ 427 %a n ¼ 365 %a P Valueb
Female 395 66.9 455 65.4 .55 292 68.4 243 66.6 .59
Age
Mean or range, y 42.9c 18–88d 43.6c 18–89d .36 44.0c 18–88d 44.9c 20–83d .31
0–19 y 5 0.8 2 0.3 .65 2 0.5 0 0 .48
20–39 y 294 49.8 335 48.1 199 46.6 157 43.0
40–59 y 216 36.6 263 37.8 165 38.6 153 41.9
60–79 y 69 11.7 87 12.5 55 12.9 52 14.2
80–99 y 6 1.0 9 1.3 6 1.4 3 0.8
Marital status .04 .03
Single 124 21.1 113 16.3 88 20.7 50 13.7
Married 423 71.9 536 77.1 308 72.5 292 80.0
Divorced 35 6.0 32 4.6 24 5.6 15 4.1
Widowed 6 1.0 14 2.0 5 1.2 8 2.2
Education .31 .96
Primary school 23 3.9 31 4.5 16 3.8 14 3.9
Secondary school 128 21.9 172 25.1 90 21.2 79 22.0
University 434 74.2 481 70.3 318 75.0 266 74.1
Main occupation .30 .90
Worker 478 81.2 580 83.6 352 82.6 300 82.2
Student 16 2.7 16 2.3 8 1.9 9 2.5
Unemployed/retired 78 13.2 88 12.7 57 13.4 50 13.7
Other 17 2.9 10 1.4 9 2.1 6 1.6
aPercentages may not total to 100 because of rounding.
bPearson’s chi-square exact 2-sided, except for sex (Fisher’s exact 2-sided mid-P) and continuous age (Gosset’s t test).
cMean age.
dAge range.
Table 3. Prevalence and OR of IBS and CF With Subgroups and Combinations of the Conditions 10 Years After a Giardia
lamblia Outbreak in Bergen, Norway, 2004
Condition
Alla Exposed Control subjects Unadjusted Adjustedb
n ¼ 1286 n ¼ 590 % n ¼ 696 % OR 95% CI OR 95% CI
IBS 1261 248 43.1 94 13.7 4.75 3.62–6.25 4.74 3.61–6.23
Severe IBSc 1259 54 9.4 14 2.0 4.96 2.73–9.03 5.05 2.77–9.20
CF 1279 153 26.1 73 10.5 2.99 2.20–4.05 3.01 2.22–4.08
Severe CFd 1279 43 7.3 9 1.3 6.00 2.90–12.41 5.98 2.89–12.39
IBS and CF 1255 101 17.6 19 2.8 7.44 4.49–12.32 7.46 4.51–12.36
IBS only 1255 146 25.4 75 11.0 2.76 2.03–3.74 2.74 2.02–3.72
CF only 1255 45 7.8 51 7.5 1.05 0.69–1.60 1.05 0.69–1.59
CI, confidence interval; CF, chronic fatigue; IBS, irritable bowel syndrome; OR, odds ratio.
aNumber of cases with valid data for the outcome.
bAdjusted for sex and age in a multiple logistic regression model.
cIBS limiting activities at least often was defined as severe IBS.
dCF with a fatigue score of 23 or more was defined as severe CF.
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answered at all time points and were not missing for the
variables of interest (Table 5 and Figure 1 for IBS and
Supplementary Table 3 with figure for CF). Persistent IBS
was more common among exposed (99 of 399, 25%)
than among control subjects (6 of 356, 1.7%) with an
aOR for persistent IBS among the exposed of 19.3 (95%
CI, 8.3–44.7). Persistent CF was reported among 57 of
406 (14%) of the exposed and 3 of 364 (0.82%) of the
control subjects with an aOR for CF among exposed of
20.5 (95% CI, 6.3–66.2).
The prevalence of IBS subtypes among the 248
exposed individuals with IBS after 10 years was 11% for
IBS with constipation, 44% for IBS with diarrhea, 38%
for mixed subtype, and 7% for unsubtyped. Corre-
sponding numbers for 3- and 6-year follow-ups are
available as Supplementary Table 4. IBS subtype was
stable over time in 33 of 99 exposed individuals with
persisting IBS (33%) whereas the rest shifted between
the 4 subtypes between follow-ups (see Supplementary
Tables 5 and 6 for details).
Discussion
The main finding in this study was that the preva-
lence and odds ratio of both IBS and CF remained high 10
years after the acute giardiasis. The prevalence of IBS
decreased from 3 to 6 years and 3 to 10 years after
exposure, while there was no change from 6 to 10 years.
The prevalence of CF fell over the 3 time points. Giardia
exposure was strongly associated with persistence of IBS
and CF.
Strengths and Limitations
A strength of this study was the fact that all partici-
pants in the exposed cohort had a laboratory-defined
diagnosis of giardiasis during a verified outbreak,
which is not always the case in studies of PI-IBS.5
Possible coinfection with other pathogens has not sys-
tematically been ruled out in this cohort, but we consider
the risk of coinfection to be low. Robertson et al22 found
clinically significant coinfection with Cryptosporidium
parvum unlikely. Further, this was a well-defined
outbreak where an unspecified number of the first pa-
tients from the outbreak had been investigated for bac-
terial gastroenteritis in accordance with the local
laboratory’s standard panel with a negative result. The
contaminated drinking water was purified by chlorina-
tion, which is effective against bacteria, but not Giardia.15
Despite a decreased response rate after 10 years, our
study cohorts still had a high number of participants
(590 for exposed individuals, 696 for control subjects),
which increased the power of the study. As 427 exposed
and 365 control subjects answered at all follow-up times,
this study represented a unique opportunity to follow
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time, as presented in the Sankey-diagrams (Table 5 with
Figure 1 and Supplementary Table 3 with figure).
The response rate in the exposed cohort declined
from 65% after 3 years (9) to 50% after 10 years, and
selection bias cannot be ruled out. The subgroup of
exposed who answered at all time points could possibly
be more selected than the exposed group as a whole.
However, this group had a prevalence of IBS and CF
comparable to the whole group. In a simulated scenario
with maximum bias in the exposed group
(Supplementary Table 2) we found that both IBS and CF
were still associated with exposure 10 years after
infection (ORs, 1.7 and 1.3, respectively). This finding
strengthens the conclusions of the current study. The
predominance of women in the exposed group has been
explained in part by women drinking more tap water,
increasing the probability of clinical infection.15 The fact
that the prevalence of IBS and CF remained largely
unchanged at all time points in the control group at a
level that is comparable to the Norwegian normal pop-
ulation23,24 suggests that selection bias is not a major
problem in the control group.
Baseline information about respondents in this study
was not available, including preoutbreak prevalence of
IBS, psychological profile, and other comorbidities. Three
studies from this outbreak have addressed the issue of
preoutbreak abdominal symptoms, without clear evi-
dence of an association between pre-existing abdominal
complaints and postinfectious complications.9
The control group was recruited from the same area
as the outbreak, and hence we included a question to
exclude control subjects who self-reported a physician-
verified diagnosis of giardiasis in 2004. This reduced
the probability of including control subjects with clinical
giardiasis, which could have led to an underestimation of
the association between Giardia exposure and the
outcomes.
Interpretation
The prevalence of IBS among the exposed (43%) in
our study 10 years after the acute infection is high
compared with other studies on PI-IBS. One review
found a range of prevalence of PI-IBS after epidemic in-
fections between 7% and 36%, where all the studies
included had a shorter follow-up time than 10 years.5
This unexpectedly high prevalence of IBS after 10 years
could be partly explained by a general increase in di-
agnoses of functional bowel diseases in the society as a
whole due to increasing awareness of these conditions in
the population. There was a time lag before the outbreak
was recognized,15 and some patients probably had
giardiasis for some time before they received treatment,
possibly increasing the risk for developing PI-IBS. Pre-
vious studies have concluded that chronic giardiasis or
lactose-intolerance cannot explain the high prevalence of
IBS in this cohort.9,25 Due to the heterogeneity among
studies on PI-IBS, direct comparisons of the results are
challenging. We found a strong association between
Giardia exposure and IBS 10 years after exposure. A
recently published 10-year follow-up study found a sig-
nificant association between exposure to shigellosis and
PI-IBS 1 and 3 years after the infection, but no significant
association 5, 8, or 10 years later.7 The Walkerton
outbreak had a follow-up time of 8 years, and found that
exposure to a mixture of bacterial pathogens was asso-
ciated with PI-IBS 8 years after exposure, with a preva-
lence of PI-IBS among exposed of 15.4%.6 Previous
research has suggested that bacterial pathogens cause
Table 5. Persistent, Incident and Recovered IBS After the 2004 Giardia lamblia Outbreak in Bergen, Norway Among Cases
Who Answered at All Follow-Ups (3, 6, and 10 Years After Exposure) and Are Nonmissing for the Variable IBS,
n ¼ 755
Group
Years after exposure Exposed
Control
subjects
3 6 10 n % n %
A IBS persistent IBS IBS IBS 99 24.8 6 1.7
B IBS recovered after 10 years IBS IBS No 30 7.5 9 2.5
C IBS after 3 and 10 years IBS No IBS 28 7.0 7 2.0
D IBS recovered after 6 years IBS No No 40 10.0 24 6.7
E IBS incident after 6 years No IBS IBS 19 4.8 6 1.7
F IBS incident after 6, recovered after 10 years No IBS No 19 4.8 14 3.9
G IBS incident after 10 years No No IBS 17 4.3 16 4.5
H Never IBS No No No 147 36.8 274 77.0
Total 399 100.0 356 100.0
Total prevalence of IBS in exposed group per year, %a 49.4 41.9 40.9
Total prevalence of IBS in control group per year, %a 12.9 9.8 9.8
IBS, irritable bowel syndrome.
aSum of the 4 upper red boxes in Figure 1 each year.
1070 Litleskare et al Clinical Gastroenterology and Hepatology Vol. 16, No. 7
longer lasting symptoms of PI-IBS than viral pathogens.10
Our findings suggest that PI-IBS after infection with the
parasite Giardia may have a poorer prognosis than after
both bacterial and viral infections.
Other studies have found younger age and female sex
to be risk factors for the development of PI-IBS following
infection,10 but we did not replicate this finding among
the exposed in our study. Female sex is also known as a
risk factor for IBS among sporadic cases.26 We found that
significantly more women than men had IBS in the
control group, but no sex difference in the exposed
group. This possible interaction of sex on exposure effect
on IBS was not statistically significant when performing
the Breslow-Day test.
Before the 2004 Giardia outbreak in Bergen, few
studies had investigated long-term associations between
gastrointestinal infection and CF. Previous studies on
postinfectious fatigue are heterogeneous, and the defi-
nition of CF varies. Some studies12 have investigated CFS,
not to be confused with CF as defined in our study. With
these limitations in mind, it nevertheless seems clear that
postinfectious CI is a condition8,11–14 to be considered in
the clinic, and our study adds evidence to this. While the
prevalence of IBS among the exposed in our cohort fell
somewhat from 3 to 6 years but then seemed to plateau
at a high prevalence, CF after Giardia infection seemed to
have a better prognosis, as the prevalence fell also from 6
to 10 years after acute giardiasis. The difference in
prognosis could partly be due to different therapeutic
interventions received during follow-up, but our ques-
tionnaire did not assess this.
From Table 5 and Figure 1 it is clear that there was a
considerable change to and from the criteria-based IBS
diagnosis among both the exposed and the control group
from time point to time point. This probably reflects
some of the true incident and recovered cases of IBS over
a time span, but it could also reflect the fact that although
IBS is considered a chronic condition, it is also a condi-
tion that has fluctuating symptoms over time.26 The
stability of the IBS subtype among exposed with per-
sisting IBS was also low, in line with the findings from
the 8-year follow-up of the Walkerton outbreak.6
Interestingly, there was a strong association between
exposure and persistent IBS (IBS criteria met at all 3
follow-ups). This may be due to the fact that respondents
in the exposed group on average probably had a closer
relation in time to at least 1 possible IBS causing factor
(Giardia exposure), than the control group, whose IBS
causing factor(s) were unknown.
Through follow-up of a cohort of laboratory verified
Giardia exposed and their controls at 3, 6, and 10 years
after exposure, we now have more knowledge about the
natural history of long-term complications after this
infection. IBS and CF both remained associated with
exposure even 10 years after the acute infection. The
prevalence of CF fell through all follow-ups, whereas
the IBS prevalence reached a plateau after an initial fall
in prevalence. Clinicians need to consider both these
conditions when a patient with a known history of
gastrointestinal infection presents with unexplained
symptoms even long after the acute infection is
resolved.
Supplementary Material
Note: To access the supplementary material accom-
panying this article, visit the online version of Clinical
Gastroenterology and Hepatology at www.cghjournal.org,
and at https://doi.org/10.1016/j.cgh.2018.01.022.
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Methods
Supplementary Text. Selection Bias
Analyses
Selection bias was assessed in 2!2 tables with
stratification. Response/no response after 10 years was
the outcome, and CF and IBS after 3 and 6 years,
respectively, were the independent variables. The ana-
lyses were stratified according to status as exposed or
controls. A scenario with maximum bias in the exposed
group was simulated with the prevalence of either
outcome set to be zero among nonresponders, whereas
control group nonresponders were included with an
assumed prevalence identical to that among control
group responders. These results were not adjusted, as
nonresponder responses were imputed.
Results
A higher proportion among exposed with IBS after 3
years (68%) than among exposed without IBS (60%)
responded to the 10-year follow-up (OR for response
after 10 years 1.4; 95% CI: 1.1 to 2.0). Among exposed
with IBS after 6 years 71% responded after 10 years as
compared to 64% among exposed without IBS (OR for
response after 10 years 1.4; 95% CI: 1.0 to 1.9). Among
controls no differences were found in response rate
after 10 years dependent on IBS-status after 3 or 6
years. There were no changes in response rates at 10
years among exposed after 3 or 6 years according to CF-
status. Controls with CF after 3 years were less likely to
respond after 10 years than controls without CF (46%
vs. 58%, OR for response after 10 years 0.61 CI: 0.40 to
0.95), but there was no change in response rates ac-
cording to CF-status after 6 years (Supplementary
Table 1). A scenario with maximum bias in the
exposed group resulted in an OR for IBS of 1.7 (95% CI
1.4 to 2.1) and for CF of 1.3 (95% CI 1.0 to 1.6)
(Supplementary Table 2).
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Supplementary Table 1. Cross-Tabulations on Whether Study Participants Responded or Not After 10 Years Dependent on
Response to Question on IBS/CF or Not After 3 and 6 Years, Stratified to Exposure Status
Answer After Cohort Condition
Responders After 10 Years
% n/n ORa 95% CI
3 y Exposed IBS Yes 68 235/344 1.44 1.06 to 1.95
No 60 235/392
Controls Yes 55 62/113 0.92 0.62 to 1.37
No 57 393/690
Exposed CF Yes 62 220/353 0.96 0.71 to 1.29
No 63 256/404
Controls Yes 46 42/92 0.61 0.40 to 0.95
No 58 417/721
6 y Exposed IBS Yes 71 202/285 1.39 1.00 to 1.91
No 64 274/430
Controls Yes 60 58/96 1.08 0.70 to 1.67
No 59 430/735
Exposed CF Yes 66 146/221 0.95 0.68 to 1.33
No 67 327/487
Controls Yes 54 50/93 0.78 0.51 to 1.21
No 60 442/740
CI, confidence interval; CF, chronic fatigue; IBS, irritable bowel syndrome; OR, odds ratio.
aBreslow-Day test for homogeneity of OR (exposed/controls) was negative (P > .05) for all outcomes.
Supplementary Table 2. Results From Cross-Tabulation
Analyses of IBS or CF According to
Exposure Status in a Scenario With
Maximum Bias in the Exposed
Groupa
Condition Group % n N OR 95% CI
IBS Exposed 21.4 248 1160 1.71 1.43 to 2.06
Controls 13.7 316 2307
CF Exposed 13.1 153 1171 1.28 1.03 to 1.59
Controls 10.5 243 2314
CI, confidence interval; CF, chronic fatigue; IBS, irritable bowel syndrome;
OR, odds ratio.
aA scenario with maximum bias in the exposed group was simulated with the
prevalence of either outcome set to be zero among nonresponders, whereas
control group nonresponders were included with an assumed prevalence
identical to that among control group responders.
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Supplementary Table 3 with Figure. Persistent, Incident, and Recovered CF After the 2004 Giardia lamblia Outbreak in
Norway Among Cases Who Answered at All Follow-Ups (3, 6, and 10 Years After
Exposure) and Are Nonmissing for CF (n ¼ 770) . The Thickness of the Lines in the
Figure Graphic Correspond to the Proportion of That Particular Group Relative to the
Population of 406 for the Exposed Group and 364 for the Control Group
Group
Years after exposure Exposed Controls
3 6 10 n % n %a
A) CF persistent CF CF CF 57 14.0 3 0.8
B) CF recovered after 10 years CF CF No 39 9.6 5 1.4
C) CF after 3 and 10 years CF No CF 25 6.2 3 0.8
D) CF recovered after 6 years CF No No 62 15.3 22 6.0
E) CF incident after 6 years No CF CF 13 3.2 6 1.6
F) CF incident after 6 years, recovered after 10 years No CF No 12 3.0 16 4.4
G) CF incident after 10 years No No CF 14 3.4 14 3.8
H) Never CF No No No 184 45.3 295 81.0
Total 406 100.0 364 99.8
Total prevalence of CF in exposed group per year, %b 45.1 29.8 26.8
Total prevalence of CF in control group per year, %b 9.1 8.2 7.1
CF, chronic fatigue; No, no chronic fatigue.
aPercentages did not total to 100 because of rounding.
bThe sum of the 4 upper red boxes (CF) each year.
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Supplementary Table 5. Shifts in IBS Subtype Per Year
Among Those Exposed With
Persisting IBS (n ¼ 99) After an
Outbreak of Giardiasis in Bergen,
Norway, 2004
Years after exposure
n %a3 6 10
C C C 4 4
C M C 1 1
C D D 2 2
C C M 2 2
C M M 2 2
D M C 2 2
D C D 1 1
D D D 17 17
D M D 3 3
D C M 1 1
D D M 5 5
D M M 1 1
M M C 2 2
M D D 9 9
M M D 8 8
M D M 6 6
M M M 12 12
Xb Xb Xb 21 21
Total 99 99
C, constipation; D, diarrhea; IBS, irritable bowel syndrome; M, mixed;
U, unsubtyped.
aPercentages may not total to 100 because of rounding.
bIBS subtype is a 4-level variable. With 3 follow-ups, there are 4 ! 4 ! 4 ¼ 64
possible trajectories. We therefore collapsed all trajectories containing at least
1 instance of the category unsubtyped.
Supplementary Table 4. Prevalence of IBS Subtype Per Year
Among Those Exposed With IBS





n %b n %b n %b
Constipation 34 9.6 35 12.2 26 10.5
Diarrhea 137 38.7 108 37.5 109 44.0
Mixed 161 45.5 118 41.0 95 38.3
Unsubtyped 22 6.2 27 9.4 18 7.3
Total 354 100 288 100.1 248 100.1
IBS, irritable bowel syndrome.
aDefined according to the Rome III criteria.
bPercentages may not total to 100 because of rounding.
Supplementary Table 6. Shifts in IBS Subtype Among Those
Exposed With Persisting IBS
(N ¼ 99) After an Outbreak of
Giardiasis in Bergen, Norway, 2004
Type of trajectorya n %b
Flow between C and Dc 6 6
Flow between M and Dd 32 32
Flow between M and Ce 7 7
Stable C 4 4
Stable D 17 17
Stable M 12 12
Contains unsubtypedf 21 21
Total 99 99
C, constipation; D, diarrhea; IBS, irritable bowel syndrome; M, mixed.
aThe trajectories in Supplementary Table 5 have been collapsed.
bPercentages may not total to 100 because of rounding.
cIncludes trajectories CDD, DCD, DMC, DCM.
dIncludes trajectories DMD, DDM, DMM, MDD, MMD, MDM.
eIncludes trajectories CMC, CCM, CMM, MMC.
fIncludes all trajectories containing at least 1 instance of category unsubtyped.
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Gastrointestinal infections can lead to long-term complications after 
the microbial agent has been eradicated. Post-infectious irritable 
bowel syndrome (PI-IBS) has been recognized for decades1 and is 
clinically similar to sporadic irritable bowel syndrome (IBS). Chronic 
fatigue syndrome (CFS) is another known condition following some 
infections,2 including giardiasis.3,4 Chronic fatigue (CF) is a useful 
and validated concept in epidemiologic studies where clinical exami-
nation is not feasible.5 CF has also been found to be a long-lasting 
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0v|u-1|
-1h]uom7ĹGastroenteritis has been associated with complications such as irritable 
bowel syndrome (IBS) and chronic fatigue (CF). Little is known about the implications 
for quality of life (QoL) in this setting. The aims of this study were to evaluate the as-
sociation between exposure to Giardia infection and QoL ten years after the infec-
tion, and how this related to IBS and CF.
;|_o7vĹWe followed 1252 patients with laboratory-verified Giardia lamblia infec-
tion and a matched control group for 10 years after an epidemic in Bergen, Norway, 
in 2004. The main outcome was QoL after ten years as defined by the Short-form 12 
version 2 with a physical component summary (PCS) and a mental component sum-
mary (MCS), both with range 0-100 (T-score). Regression analyses were performed 
using mixed modeling.
;!;vѴ|vĹMean PCS T-score in the exposed group (51.4; 95% CI: 50.6-52.1) was 
ƑĺѶ$Ŋv1ou;robm|v ŐƖƔѷĹƴƒĺѶ |oƴƐĺƖķP < 0.001) lower than that in the control 
group (54.2; 95% CI: 53.7-54.8). The mean MCS T-score was also 2.8 T-score points 
ŐƖƔѷĹƴƒĺѶ|oƴƐĺƖķP < 0.001) lower among the exposed (48.9; 95% CI: 48.2-49.6) 
than the controls (51.7; 95% CI: 51.1-52.4). Further analyses found that the effect of 
Giardia exposure on QoL was mediated by IBS and CF.
om1Ѵvbomvşm=;u;m1;vĹrovu;|oGiardia infection was associated with a lower 
QoL ten years later as compared to a control group, an effect that was mediated by 
IBS and CF.
  + ) !	 "
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complication after giardiasis.6–8 Few studies have investigated qual-
b| o= Ѵb=; Ő oő -=|;u ]-v|uobm|;v|bm-Ѵ bm=;1|bomvĺm; v|7 =om7
that QoL was impaired six months after Shiga toxin-producing 
Escherichia coli gastroenteritis, and that the physical QoL normalized 
after one year, whereas the mental QoL remained impaired.9 CFS 
and IBS have been shown to affect QoL.10-14
In 2004, one of the main drinking-water reservoirs of the city of 
Bergen, Norway, was contaminated by Giardia lamblia cysts. IBS and 
CF were associated with exposure to Giardia infection as long as ten 
years after the outbreak,6 but how this may affect QoL is not well 
known. The main aim of this study was to evaluate the association 
between exposure to Giardia infection and QoL ten years after the 
Bergen outbreak, as compared to a control group. The secondary 




This was a prospective cohort study following 1252 infected patients 
with laboratory-verified Giardia lamblia (the exposed group) and a 
control group three, six, and ten years after an epidemic of giardiasis 
in Bergen, Norway, 2004. The group of 2504 controls was matched 
2:1 by sex and age to the exposed group and was recruited from the 
Bergen area by Statistics Norway, on our request. We only included 
participants who were 18 years or older in 2014 for this study.
Patients consented to participate upon answering the question-
m-bu;ĺ$_;!;]bom-Ѵollb||;; =ou|_b1v bm;7b1-Ѵ!;v;-u1_-r-
proved the study (ref.no. 2014/1372).
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ured by the Short-form 12 version 2 (SF-12v2). The SF-12v2 
consists of a physical component summary (PCS) and a mental 
component summary (MCS), measuring physical and mental QoL, 
respectively. The PCS and MCS range from 0-100 and are based 
on a 2009 US norm for QoL with a mean of 50 and a standard 
deviation of 10. The points on the scale are referred to as T-score 
points. The two scores are based on the score of eight sub-scales, 
that is, physical functioning, role-physical (how the physical QoL 
affects daily functioning), bodily pain, general health, vitality, so-
cial functioning, role-emotional (how the mental QoL affects daily 
=m1|bombm]őķ-m7l;m|-Ѵ_;-Ѵ|_ĺѴ|_o]_-ѴѴ;b]_|v0Ŋv1-Ѵ;v1om-
tribute to the scoring of both PCS and MCS, the former three have 
the strongest correlation with PCS, and the latter three have the 
v|uom];v| 1ouu;Ѵ-|bomb|_"ĺ Ѵvoķ |_; v; o= -m ou|_o]om-Ѵ
scoring algorithm applies negative weights to sub-scales most 
strongly correlated with MCS when scoring the PCS (and vice 
versa), ensuring validity in discriminating between physical and 
mental health outcomes. In addition, PCS and MCS scores were 
both dichotomized based on a score of 45 and above, or lower than 
45. Scoring of the QoL variables was done using the QualityMetric 
;-Ѵ|_|1ol;vŤ"1oubm]"o=|-u;ƔĺƏķ-vu;1oll;m7;70|_;
developers of the SF-12.15 The software’s option to estimate miss-
ing scores was used. We used PCS and MCS means and stand-
ard deviations from Gandek et al16 to compare our results with 
a Norwegian norm. The SF-12 was translated to Norwegian and 
validated for use on a Norwegian population as part of that study. 
The developers of the SF-12 suggest that when comparing QoL 
between groups, a difference in three or more T-score points is 
considered clinically important.15
IBS was defined according to the Rome-III criteria.17 Respondents 
were defined as having IBS if reporting recurrent abdominal pain or 
discomfort for at least three days per month in the last three months, 
associated with at least two or more of the additional IBS-criteria 
related to defecation or stool changes, if onset of symptoms was at 
least 6 months prior to completing the questionnaire.
CF was defined using the Fatigue Questionnaire.5 This validated 
questionnaire consists of 13 questions, where 11 of these measure 
different aspects of fatigue on a four-item Likert scale: “less than 
usual” (0), “as usual” (1), “more than usual” (2), and “much more than 
usual” (3). The sum of these scores constitutes the total fatigue score 
with a range of 0-33. The Likert scale scores are also dichotomized 
(0 and 1 into 0, 2 and 3 into 1), and CF is defined as a dichotomized 
score of four or more and a duration of six months or more. Cases 
with 4 or less missing answers on the 11 fatigue-related questions 
were included, and the missing responses for the questions were 
estimated based on the average for non-missing responses to that 
particular question.
IBS and CF were assessed at follow-ups of 3, 6, and 10 years 
after the outbreak, whereas QoL was assessed only at the 10-year 
follow-up.
To better assess and illustrate the relationships between ex-
posure status, IBS and CF (all dichotomous), and the outcomes 
PCS and MCS, the three former variables were combined into 
one eight-category variable with the categories “Neither condi-
tion among controls” (reference category in regression analyses), 
“Neither condition among exposed”, “IBS-only among controls”, 
“IBS-only among exposed”, “CF-only among controls”, “CF-only 
Key Points
• Irritable bowel syndrome (IBS) and fatigue are known 
complications following gastroenteritis. This paper as-
sessed the quality of life ten years after a Giardia lamblia 
gastroenteritis and how this related to IBS and fatigue.
• Quality of life was lower among patients who suffered 
from gastroenteritis, mainly due to the development of 
IBS and fatigue.
• Clinicians should be aware that gastroenteritis can have 
a lasting impact on quality of life in patients, especially in 
those who have long-term complications.
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among exposed”, “IBS and CF among controls”, and “IBS and CF 
among exposed”.
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(continuous and categorized according to the SF12v2 user’s man-
ual15), marital status (four categories), level of education (three cate-
gories), and source of income (four categories).
ƑĺƒՊ|Պm-Ѵv;v-m7v|-|bv|b1-Ѵl;|_o7v
We calculated descriptive statistics as percentage, mean, standard 
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exact 2-sided mid-p test in 2 × 2 tables for binary outcomes18 and 
Pearson’s chi-square exact 2-sided test for multilevel outcomes.
To account for dependence between matched subjects, we used 
mixed modeling with unstructured covariance when performing re-
gression analyses.
ѴѴl;-mvru;v;m|;7-u;|_;o0v;u;7l;-mvķ|o]b;|_;u;-7;u
the unadjusted values of PCS and MCS for the different study 
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as they are the results of regression analyses, and hence, they do 





PŊ-Ѵ;bn %a n %a
Response rate 592/1176 50.3 708/2330 30.4
Female sex 395 66.9 455 65.4 c
];bm;-uv
Mean/range 42.9d 18-88d 43.6d 18-89d c
18-24 12 2.0 9 1.3 c
25-34 174 29.5 184 26.4
35-44 189 32.0 258 37.1
45-54 103 17.5 98 14.1
55-64 72 12.2 88 12.6
65-74 32 5.4 44 6.3
75-89 8 1.4 15 2.2
Marital status
Single 124 21.1 113 16.3 0.04
Married 423 71.9 536 77.1
	bou1;7 35 6.0 32 4.6
Widowed 6 1.0 14 2.0
71-|bom
Primary school 23 3.9 31 4.5 0.31
Secondary school 128 21.9 172 25.1
University 434 74.2 481 70.3
Main occupation
Worker 478 81.2 580 83.6 0.30
Student 16 2.7 16 2.3
Unemployed/
retired
78 13.2 88 12.7
|_;u 17 2.9 10 1.4
IBS prevalence 248 43.1 94 13.7 <0.001
CF prevalence 153 26.1 73 10.5 <0.001
CF, chronic fatigue; IBS, irritable bowel syndrome.
aPercentages may not total to 100 because of rounding. 
bPearson’s chi-squared exact 2-sided, except for IBS and CF (Fisher’s exact 2-sided mid-p). 
cƷmo|-rrѴb1-0Ѵ;ĸu;vrom7;m|v;u;l-|1_;7omv;-m7-];ķ-m7_;m1;ķ;7b7mo|r;u=oul
significance testing for these variables. 
dMean age, age range. 
$ ƐՊResponse rate, 
demographics, and prevalence of irritable 
bowel syndrome and chronic fatigue of 
the cohorts ten years after a Giardia 
lamblia outbreak in Bergen, Norway, in 
2004
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Confounding was evaluated with regression analyses. Level of 
education, source of income, and marital status were considered 
potential confounders. Sex and age were matched for and hence 
were not considered potential confounders. Possible interactions 




set to 0.05. The analyses were done using IBM SPSS Statistics for 
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Response rate, demographic data, prevalence of IBS and CF, and 
non-responder analyses of this cohort ten years after the Giardia 
outbreak have been published previously,6 and some of these data 
are summarized in Table 1. For PCS, there were 0.3% missing values 
among exposed (2/590) and 0.9% missing among controls (6/696). 
For MCS, there were no missing values. For IBS, there were 14 miss-
ing out of 590 (2.4%) among exposed and 11 of 696 (1.6%) among 
controls. For CF, the corresponding numbers were 3/590 (0.5%) and 
4/696 (0.6%), respectively.
Mean QoL T-score for the entire cohort regardless of group was 
ƔƑĺƖŐ"	ĹѶĺƕő=ou"-m7ƔƏĺƓŐ"	ĹƖĺƐő=ou"ĺ
Mean PCS T-score in the exposed group (51.4; 95% CI: 50.6-52.1) 
-vƑĺѶ$Ŋv1ou;robm|vŐƖƔѷĹƴƒĺѶ|oƴƐĺƖĸP < 0.001) lower than 
for the control group (54.2; 95% CI: 53.7-54.8). The mean MCS T-
v1ou;-v-ѴvoƑĺѶ$Ŋv1ou;robm|v ŐƖƔѷĹƴƒĺѶ |oƴƐĺƖķP < 0.001) 
lower among the exposed (48.9; 95% CI: 48.2-49.6) than the controls 
(51.7; 95% CI: 51.1-52.4; Figure 1).
“Neither condition among controls” (after ten years) was the ref-
erence category in regression analyses and was the subgroup with 
the highest QoL for both PCS and MCS (Tables 2 and 3), with mean 
T-scores of 55.4 (95% CI: 54.9-55.9) and 53.4 (95% CI: 52.8-54.0), 
respectively. The exposed with neither condition after ten years 
_-7|_;v-l;"Ől;-m$Ŋv1ou;7b==;u;m1;ĹƴƏĺƐĸƖƔѷĹƴƐĺƑ|o
1.0; PŊ-Ѵ;ĹƏĺѶƓőķ0|-Ѵo;u"Ől;-m$Ŋv1ou;7b==;u;m1;ĹƴƐĺƓĸ
ƖƔѷĹƴƑĺƔ|oƴƏĺƑĸP-value: 0.023) than the reference category. 
ѴѴo|_;u1-|;]oub;v bm|_;;b]_|Ŋ1-|;]ou-ub-0Ѵ;7;v1ub0;7bm|_;
methods section had a lower QoL than the reference category, both 
for PCS and for MCS. This eight-category variable was also analyzed 
with PCS and MCS as a dichotomized outcome with a T-score below 
ƓƔrobm|voumo|Ő$-0Ѵ;vƑ-m7ƒőĺ;uƔƏѷo=|_;u;vrom7;m|vbm
the category “IBS and CF among exposed” had a PCS lower than 
45 points. For MCS, all categories comprising respondents with CF-
only or CF and IBS had over 50% of respondents with an MCS score 
below 45.
In a regression model with exposure status, IBS and CF after ten 
years as independent variables, and PCS as the outcome, there was 
 &! ƐՊ0v;u;7l;-m"-m7"b|_ƖƔѷ1om=b7;m1;bm|;u-ѴvƐƏ;-uv-=|;u-b-u7b-Ѵ-l0Ѵb-o|0u;-hbm;u];mķou-ķ
in 2004, as compared to a Norwegian Norma. PCS, physical component summary; MCS, mental component summary; IBS, irritable bowel 
vm7uol;ĸķ1_uomb1=-|b];ĸomķ1om|uoѴvĸrķ;rov;7|oGiardia. aSF-12 scores for a Norwegian sample population from Gandek et al.16 
The horizontal lines on the figure are one-third of a standard deviation T-score points under/over the mean T-score from that population. 
	o||;7=ou"ķvoѴb7=ou"ĺbThe first four columns (with bold labels) depict PCS and MCS according to exposure status. The next sixteen 
columns depict PCS and MCS according to the eight-category variable described in the methods section
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no longer a significant effect of exposure status on the outcome with 
a mean PCS that was 0.50 T-score points lower among the exposed 
ŐƖƔѷĹƴƐĺƓ|oƏĺƓƏĸP-value: 0.28). The same was found for mean 
MCS, which was 0.75 T-score points lower among the exposed (95% 
ĹƴƐĺƕ|oƏĺƑƑĸP-value: 0.13).
We found a significant interaction between CF and exposure 
status on both measures of QoL (Table 4). The mean PCS among 
|_ov;b|_bm|_;;rov;7]uor-vƴƖĺƑrobm|vѴo;u|_-m=ou
respondents without CF, whereas for controls, the difference was 
ƴƓĺƕ ŐP < 0.001). For MCS, the relationship was inverse: The mean 
"-lom]|_ov;b|_ bm|_;1om|uoѴ]uor-vƴƐƏĺƖ$Ŋv1ou;
points lower than for respondents without CF, whereas for exposed, 
|_;7b==;u;m1;-vƴѶĺƏŐP-value: 0.027). We found no significant in-
teraction between IBS and exposure on QoL (P-value: 0.78 for PCS; 
P-value: 0.34 for MCS).
We found no interactions of sex on the association between ex-
posure and PCS (P-value: 0.16) or MCS (P-value: 0.39), nor of age on 
the same associations (P-values: 0.10 and 0.056, respectively).
We also analyzed how exposure status, IBS and CF after three 
and six years related to QoL after ten years (Table S1). We found 
that for the eight-category variable with “Neither condition among 
controls” at each follow-up as reference category, the findings (in 
terms of direction and statistical significance of the results) were 
similar to the results above (after ten years) with some exceptions. 
In addition to the category, “Neither condition among exposed” also 
the category “IBS-only among controls” after six years had the same 
PCS as the reference category. The categories “Neither condition 
among exposed” and “IBS-only among controls” after both three and 
six years had the same MCS after ten years as the reference cate-
gory. Corresponding analyses on dichotomized PCS and MCS after 
$ ƑՊQuality of life, physical component summary analyzed by simple regression analyses, as continuous and dichotomized variable 





n % ! ƖƔѷ
Neither condition among 
controls
532 55.4a 54.9 to 55.9 ref 35 6.6 ref ref
Neither condition among 
exposed
280 ƴƏĺƐ ƴƐĺƑ|oƐĺƏ 0.84 18 6.4 1.0 0.6-1.8
IBS-only among controls 75 ƴƓĺƓ ƴѵĺƑ|oƴƑĺƔ <0.001 17 22.7 4.4 2.3-8.3
IBS-only among exposed 146 ƴƒĺƒ ƴƓĺƕ|oƴƐĺƖ <0.001 20 13.7 2.4 1.3-4.3
CF-only among controls 50 ƴƔĺƐ ƴƕĺƒ|oƴƑĺƖ <0.001 16 32.0 6.1 3.0-12.2
CF-only among exposed 45 ƴѶĺѵ ƴƐƏĺƖ|oƴѵĺƑ <0.001 22 48.9 14.0 7.1-27.6
IBS and CF among controls 18 ƴƕĺƔ ƴƐƐĺƏ|oƴƒĺƖ <0.001 6 33.3 6.9 2.4-20.2
IBS and CF among exposed 101 ƴƐƒĺƐ ƴƐƓĺѶ|oƴƐƐĺƔ <0.001 55 54.5 17.4 10.3-29.5
CF, chronic fatigue; IBS, irritable bowel syndrome; PCS, physical component summary; Ref, reference group.
aMean in reference group of eight-category exposure variable. 
$ ƒՊQuality of life, mental component summary analyzed by simple regression analyses, as continuous and dichotomized variable 





n % ! ƖƔѷ
Neither condition among 
controls
536 53.4a 52.8 to 54.0 ref 67 12.5 ref ref
Neither condition among 
exposed
282 ƴƐĺƓ ƴƑĺƔ|oƴƏĺƑ 0.023 50 17.7 1.6 1.0-2.3
IBS-only among controls 75 ƴƒĺѶ ƴƔĺѶ|oƴƐĺѶ <0.001 15 20.0 1.7 0.9-3.3
IBS-only among exposed 146 ƴƒĺѵ ƴƔĺƐ|oƴƑĺƐ <0.001 33 22.6 2.1 1.3-3.3
CF-only among controls 51 ƴƐƑĺƒ ƴƐƓĺƕ|oƴƐƏĺƏ <0.001 30 58.8 9.6 5.2-17.8
CF-only among exposed 45 ƴƖĺѶ ƴƐƑĺƑ|oƴƕĺƒ <0.001 23 51.1 7.6 4.0-14.4
IBS and CF among controls 19 ƴƐƏĺƐ ƴƐƒĺѶ|oƴѵĺƒ <0.001 13 68.4 15.9 5.9-43.1
IBS and CF among exposed 101 ƴƐƐĺƔ ƴƐƒĺƒ|oƴƖĺѶ <0.001 62 61.4 11.4 7.1-18.4
CF, chronic fatigue; IBS, irritable bowel syndrome; MCS, mental component summary; Ref, reference group.
aMean in reference group of eight-category exposure variable. 
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three and six years are found in Table S2. The effect of exposure on 
QoL after ten years was absent when controlling for IBS and CF after 
three and six years in a regression model, with the exception of the 
analysis after 6 years, where MCS after ten years was significantly 
reduced when controlling for IBS and CF after 6 years. The interac-
tion between exposure and CF on QoL was not found after three or 
six years (Table S3).
Scores on the sub-scales most strongly associated with MCS were 
assessed descriptively to further elucidate the above-mentioned in-
teraction between exposure status and CF on QoL (Table S4). The 
“vitality” subdomain had the lowest score, but this was rather similar 
between exposed and controls with CF-only (mean T-score 38.1 vs 
38.4). The subdomain “mental health” was lower among controls with 
CF-only (44.9) than among exposed with CF-only (48.2).
We found no confounding of our results by the demographic 
variables marital status, level of education, and source of income.
ƓՊ |Պ	"&""
We found a lower QoL among giardiasis-exposed persons ten years 
after the exposure, as compared to a control group. This effect of 
the exposure to giardiasis on QoL was mediated by IBS and CF. For 
the association between exposure and QoL, there was an interaction 
between CF and exposure, as the reduction of physical QoL due to 
CF was larger among exposed than controls. The opposite was found 
for mental QoL.
ƓĺƐՊ|Պm|;uru;|-|bom
We found that exposure to Giardia lamblia was associated with a 
Ѵo;u o|;m;-uvѴ-|;u-v1olr-u;7|o-1om|uoѴ]uorĺo;;uķ
the difference between the exposed and the controls for both PCS 
and MCS at 2.8 T-score points was below the proposed thresh-
old of 3 T-score points that is considered clinically significant. The 
mean PCS for the control cohort was higher than the norm for the 
Norwegian population, whereas the mean PCS among exposed and 
the mean MCS regardless of exposure group were clinically similar to 
this norm.16 This may in part be explained by the fact that our study 
population is relatively young. There is a slight decrease in PCS with 
age in normal populations, whereas MCS increases somewhat.16
rov;7_o_-7m;b|_;u1om7b|bom_-7-vblbѴ-u"|o1om-
trols with neither condition, whereas the MCS was slightly lower 
=ou |_; ;rov;7ĺo;;uķ 0o|_ |_;v; ]uorv _-7 - o _b]_;u
than or equal to a Norwegian population norm. We found a trend 
that the presence of IBS alone lowered the QoL in both the ex-
posed and control group, but less than CF alone did. The lowest 
QoL was found among exposed with both IBS and CF, both for 
PCS (42.2) and for MCS (41.9), as well as for CF-only among con-
trols, with an MCS of 41.1. The PCS at 42.2 is comparable to that 
found in other conditions such as type 2 diabetes and recent myo-
cardial infarction.19 The MCS scores in the two above-mentioned 
]uorv ;u; Ѵo;u |_-m |_; 1|o== -| ƽƓƑ$Ŋv1ou; robm|v v;7
to classify people as being at risk for clinical depression in one 
study.20 Respondents with IBS-only had a QoL comparable to a 
$ ƓՊPhysical component summary and mental component summary according to chronic fatigue status at ten years follow-up, in 
exposed and control cohorts of the Giardia lamblia outbreak in Bergen, Norway, in 2004a







PCS rov;7 +;v 146 43.7 41.7 45.6 <0.001 ƴƓĺƔ
No 426 54.2 53.5 54.8
	b==;u;m1;d ƴƖĺƑ ƴƐƏĺƕ ƴƕĺƕ
Control +;v 68 49.7 47.1 52.2
No 607 54.8 54.3 55.4
	b==;u;m1;d ƴƓĺƕ ƴѵĺѵ ƴƑĺƕ
MCS rov;7 +;v 146 42.4 40.9 43.9 0.027 2.9
No 428 51.3 50.5 52.0
	b==;u;m1;d ƴѶĺƏ ƴƖĺѵ ƴѵĺƓ
Control +;v 70 41.7 39.3 44.1
No 611 52.9 52.3 53.6
	b==;u;m1;d ƴƐƏĺƖ ƴƐƑĺƖ ƴѶĺƖ
CF, chronic fatigue; CI, confidence interval; MCS, mental component summary (0-100); PCS, physical component summary (0-100).
aIn a linear regression model including the factors cohort (exposed/control), irritable bowel syndrome (yes/no), CF (yes/no), and the interaction term 
cohort ×CF. 
bInteraction between cohort and CF on the outcomes PCS and MCS. 
cThe difference in quality of life between CF and no CF among exposed, minus that among controls. 
d;-mv-u;o0v;u;7ķb|_ĺ	b==;u;m1;v-u;;v|bl-|;7bm-lb;7Ѵbm;-ulo7;Ѵ-m7_;m1;7omo|m;1;vv-ubѴ;t-Ѵo0v;u;7l;-m-Ѵ;=oulbmv
mean value for no CF. 
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Norwegian norm regardless of exposure status and comparable to 
a subgroup of IBS patients with low IBS-symptom severity and no 
comorbidities in another study on IBS and QoL.10 The PCS of the 
respondents with IBS-only in our study is also comparable to that 
of a group of IBS non-consulters in a study by Rey et al,21 whereas 
the MCS is higher in our group. This could be explained by the 
fact that we have subgrouped our respondents into neither condi-
tion, IBS-only, CF-only or a combination of the two conditions. The 
MCS among respondents with IBS dropped markedly when they 
have comorbid CF, to a level comparable to that of Rey et al’s IBS 
non-consulters where CF comorbidity is unknown.
The fact that the effect of exposure status disappeared in mul-
tiple regression analysis with IBS and CF included in the model sup-
ports the choice of these conditions as clinically relevant markers of 
the consequences of the Giardia epidemic. IBS and CF can be seen as 
mediators of the effects of Giardia exposure on QoL.
We found an interaction by CF on the effects of exposure on 
QoL in that the reduction in PCS score among respondents due to 
CF was significantly larger among the exposed than among controls. 
For MCS, the relationship was opposite, the reduction was signifi-
1-m|ѴѴ-u];u-lom]1om|uoѴv|_-m|_;;rov;7b|_ĺrovvb0Ѵ;
explanation for this could be that although both groups probably 
have a multifactorial cause for their CF, the respondents with CF 
among the exposed have a more specific organic etiology for their 
condition (ie, Giardia), whereas among controls mental factors could 
be more important. This notion is supported by the fact that the 
subdomain “mental health” was lower among controls with CF-only, 
than among exposed with CF-only (Table S4).
ƓĺƑՊ|Պ"|u;m]|_v-m7blb|-|bomv
m;v|u;m]|_o=|_bvv|7-v|_-||_;v;o=-1om|uoѴ]uorl-7;
the unfortunate event of an outbreak simulate a natural experiment. 
The number of participants in both groups was high, and all of the 
exposed had a laboratory-confirmed diagnosis. The longitudinal as-
pect of the study variables IBS and CF (measured after three, six, and 
ten years) makes causal inferences about the relationship between 
these conditions and QoL after ten years plausible. We used the 
validated SF-12 to measure generic QoL. We performed the scor-
ing using the developers recommended algorithm, with the 2009 
US norm. The fact that the measure is generic, widely used and has 
a standardized scoring algorithm, makes direct comparisons of our 
scores to other studies on various patient groups using the SF-12 or 
SF-36 possible.15
The response rate in the exposed group (50%) is a source of pos-
sible bias, but is deemed acceptable and as expected for this kind 
of survey.22 The control group response rate is lower (30%), and we 
have made the case against selection bias in a previous study on the 
same cohort.6 Ѵvoķ u;1;m| u;v;-u1_ v]];v|v |_-| - 7;1Ѵbmbm] u;-
sponse rate does not necessarily imply increasing bias in analyses of 
associations, although simple distributional data may suffer.22
The demographic variables recorded in our study (marital sta-
tus, level of education, source of income) were measured after the 
exposure and hence could in part be affected by the exposure, mak-
ing their role as confounders questionable.
QoL, IBS, and CF were all measured at the same time point, 
10 years after the exposure. This makes inferences about the re-
lationships between these outcomes less certain. We therefore 
included results from analyses of IBS and CF measured at time-
points three and six years after exposure and their effect on QoL 
after 10 years as well. In terms of direction of the effect and sta-
tistical significance, the results from these analyses were generally 
similar to our main findings, except for the fact that the interaction 
between CF and exposure on QoL was only found after 10 years. 
Nevertheless, we believe that the longitudinal analyses support the 
notion of IBS and CF as causes of reduced QoL and justify discussing 
the role of IBS and CF as mediators of the effect of exposure on QoL, 
as well as CF as an interacting variable on the association between 
exposure status and QoL.
ƔՊ |Պ&"
We found a lower QoL among the exposed 10 years after giardiasis 
as compared to a control group, and this was mediated by IBS and CF. 
There was furthermore a significant interaction of CF on the associa-
tion between the exposure and QoL. The effect of having CF in re-
ducing the physical QoL was larger among the exposed than among 
controls, whereas for mental QoL, the opposite was found. The find-
ings in this study support the importance of investigating whether 
patients suffer from PI-IBS and CF after giardiasis, as these compli-
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Errors in papers 1 and 2

Errors in papers 1 and 2 
The following errors were found in paper 1 after publication: 
1. In the abstract under "methods" we state that we have used "bivariate" and 
"multivariate" analyses, although the more correct terms are "univariable" and 
"multivariable". 
2. Under "participants" on page two we state that four controls were excluded, 
when the correct number is five. 
3. Under "statistical analyses" on page three we state that confounders evaluated 
were: "status as student or not in 2004, age, gender, work, income and level of 
education", where "income" should have been replaced by "marital status". 
4. In paragraph four on page four we state that "vegetables" are significantly 
associated with exposure in the no-IBS stratum, but this is incorrect. The 
information is correctly displayed in Table 4. 
5. There is an error in the "d" footnote in Table 2, where the text "is reasonably 
high, however" has been inserted between "Bresl" and "ow-Day". This is a 
post-proof error. Despite our repeated requests for amendment, the publisher 
has not responded. 
The following error was found in paper 2 after publication: 
1. On page 1071, paragraph three, we state that "...it nevertheless seems clear that 









   Enslig    Gift/samboer   Skilt/separert   Enke/enkemann
 
2. Hva er det høyeste utdanningsnivå du har påbegynt?
  Grunnskole   Videregående skole    Universitet eller høyskole
  
3. Hvilken hovedinntektskilde har du?
   Arbeidstaker    Student/skoleelev/militær     Alderspensjonist 
   Selvstendig næringsdrivende    Arbeidsledig    Annet
   Hjemmeværende    Uføretrygdet
  
4. Var du student høsten 2004?
   Nei                     Ja, fulltid          Ja, deltid
5. For kvinner: Er du gravid nå?
   Nei         Ja                      Usikker
Institutt for samfunnsmedisinske fag og Institutt for indremedisin
Universitetet i Bergen
Kalfarveien 31, 5018 BERGEN, Tlf: 55 58 61 00
Hvor sannsynlig er det at du døser av eller sovner i følgende situasjoner, i motsetning til kun å føle deg trett? 
Spørsmålene gjelder din vanlige måte å reagere på i den senere tid. Selv om du ikke har gjort noe av dette i den siste 








Stor sjanse for 
å døse/sovne
  6.  Sitte og lese
  7.  Se på TV
  8.  Sitte, inaktiv på et offentlig sted
       (for eksempel teater eller et møte)
  9.  Som passasjer på en en-times biltur uten pause
10.  Legge deg for å hvile om ettermiddagen hvis
       omstendighetene tillater det
11.  Sitte og snakke med noen
12.  Sitte stille etter lunsj (uten å ha inntatt alkohol)
13.  I en bil, som har stoppet for noen få minutter i
       trafi kken
  14. Hvor mye søvn trenger du for å være opplagt?   ……….. timer  
  15. I løpet av siste måned, hvor ofte har du vært plaget av søvnløshet?
              Aldri eller sjelden           1-2 ganger i måneden       Omtrent en gang i uken       Mer enn en gang i uken












Vi vil gjerne vite om du har følt deg sliten, svak eller i mangel av overskudd den siste måneden. Vennligst besvar 
ALLE spørsmålene ved å krysse av for det svaret du synes passer best for deg. Vi ønsker at du besvarer alle 
spørsmålene selv om du ikke har hatt slike problemer. Hvis du har følt deg sliten lenge, ber vi om at du
sammenlikner deg med hvordan du følte deg sist du var bra. (Ett kryss for hver linje) 
16. Har du problemer med at du føler deg sliten?
   Mindre enn vanlig           Ikke mer enn vanlig           Mer enn vanlig          Mye mer enn vanlig
17. Trenger du mer hvile?
   Nei, mindre enn vanlig          Ikke mer enn vanlig           Mer enn vanlig          Mye mer enn vanlig
18. Føler du deg søvnig eller døsig?
   Mindre enn vanlig             Ikke mer enn vanlig           Mer enn vanlig          Mye mer enn vanlig
19. Har du problemer med å komme i gang med ting?
   Mindre enn vanlig           Ikke mer enn vanlig           Mer enn vanlig          Mye mer enn vanlig
20. Mangler du overskudd?
   Ikke i det hele tatt           Ikke mer enn vanlig           Mer enn vanlig          Mye mer enn vanlig
21. Har du redusert styrke i musklene dine?
   Ikke i det hele tatt           Ikke mer enn vanlig           Mer enn vanlig          Mye mer enn vanlig
22. Føler du deg svak?
   Mindre enn vanlig           Som vanlig                         Mer enn vanlig          Mye mer enn vanlig
23. Har du vansker med å konsentrere deg?
   Mindre enn vanlig           Som vanlig                         Mer enn vanlig          Mye mer enn vanlig
24. Forsnakker du deg i samtaler?
   Mindre enn vanlig           Ikke mer enn vanlig           Mer enn vanlig          Mye mer enn vanlig
25. Er det vanskeligere å fi nne det rette ordet?
   Mindre enn vanlig           Ikke mer enn vanlig           Mer enn vanlig          Mye mer enn vanlig
26. Hvordan er hukommelsen din?
   Bedre enn vanlig           Ikke verre enn vanlig         Verre enn vanlig        Mye verre enn vanlig
27. Hvis du føler deg sliten for tiden, omtrent hvor lenge har det vart? (Ett kryss)
    Mindre enn én måned    Fra ett år inntil tre år
    Fra én måned inntil seks måneder    Tre år eller mer (før oktober 2004)
    Fra seks måneder inntil ett år
 
 
28. Hvis du føler deg sliten for tiden, omtrent hvor mye av tiden kjenner du det? (Ett kryss)
    25 % av tiden    75 % av tiden
    50 % av tiden    Hele tiden
Slitenhet
 29. Har du eller har du hatt astma?                    Nei      Ja       Usikker
30. Hvis ja, er dette bekreftet av lege?       Nei      Ja
31. Har du brukt astma-medisiner siste måned?
(spray, pulver/væske til inhalasjon, tabletter)      Nei      Ja 
32. Har du eller har du hatt høysnue eller neseallergi?     Nei      Ja       Usikker
Astma og allergi
Mageplager siste tre måneder
33. I løpet av de siste 3 måneder, hvor ofte har du følt
 deg ubehagelig mett etter et vanlig stort måltid?
      Aldri  ¤ Gå til spørsmål 35
      Mindre enn 1 dag i måneden  
      En dag i måneden
      2-3 dager i måneden  
      En dag i uka
      Mer enn en dag i uka 
      Hver dag
34. Har du hatt denne ubehagelige metthets-følelsen
 etter måltid i 6 måneder eller lenger? 
      Nei
      Ja
35. I løpet av de siste 3 måneder, hvor ofte har du ikke
 kunnet fullføre et vanlig stort måltid?
      Aldri  ¤ Gå til spørsmål 37
      Mindre enn 1 dag i måneden  
      En dag i måneden
      2-3 dager i måneden  
      En dag i uka
      Mer enn en dag i uka 
      Hver dag
36. Har du hatt dette problemet med ikke å kunne
 fullføre et vanlig stort måltid i 6 måneder eller lenger? 
      Nei
      Ja
37. I løpet av de siste 3 måneder, hvor ofte har du hatt
 smerter eller brenning midt i magen, over navlen, men
  ikke i brystet?
      Aldri  ¤ Gå til spørsmål 46 (på neste side)
      Mindre enn 1 dag i måneden  
      En dag i måneden
      2-3 dager i måneden  
      En dag i uka
      Mer enn en dag i uka 
      Hver dag
38. Har du hatt denne smerten eller brenningen i
 6 måneder eller lenger? 
    Nei
    Ja
39. Kom og forsvant denne smerten eller
 brenningen fullstendig i løpet av samme dag?
    Sjelden/aldri
    Noen ganger
    Ofte
    Det meste av tiden
    Alltid
40. Hvor alvorlig var vanligvis smerten eller
 brenningen i midten av magen, over navlen?
    Svært mild
    Mild
    Moderat
    Sterk 
    Svært sterk
41. Ble denne smerten eller brenningen påvirket av
 spising?
    Ikke påvirket av spising
    Mer smerter etter spising
    Mindre smerter etter spising
42. Ble denne smerten eller brenningen lindret av å
 ta syrenøytraliserende midler?
    Sjelden/aldri
    Noen ganger
    Ofte
    Det meste av tiden
    Alltid
43. Ble denne smerten eller brenningen vanligvis
 bedre eller forsvant den etter at du hadde hatt
 avføring eller luftavgang fra endetarmen?
    Sjelden/aldri
    Noen ganger
    Ofte
    Det meste av tiden
    Alltid
44. Når denne smerten eller brenningen begynte,
  hadde du vanligvis endring i antall avføringer
  (enten hyppigere eller sjeldnere avføring)?
    Sjelden/aldri
    Noen ganger
    Ofte
    Det meste av tiden
    Alltid
45. Når denne smerten eller brenningen begynte,
  hadde du vanligvis løsere eller hardere avføring?
    Sjelden/aldri
    Noen ganger
    Ofte
    Det meste av tiden
    Alltid
46. Har lege diagnostisert sykdom i spiserør eller
  magesekk hos deg siste 3 år? 
    Nei
    Ja
Hvis ja, hva slags sykdom: 
………………………………………………
47. I løpet av siste 3 måneder, hvor ofte har du hatt
 plagsom kvalme?
    Aldri  
    Mindre enn 1 dag i måneden  
    En dag i måneden
    2-3 dager i måneden  
    En dag i uka
    Mer enn en dag i uka 
    Hver dag
48. I løpet av siste tre måneder, hvor ofte har du hatt
 ubehag eller smerter noe sted i magen?
    Aldri  ¤ Gå til spørsmål 58 
    Mindre enn 1 dag i måneden  
    En dag i måneden
    2-3 dager i måneden  
    En dag i uka
    Mer enn en dag i uka 
    Hver dag
49. Har du hatt kun smerter (ikke ubehag eller en
  blanding av ubehag og smerter)?
    Sjelden/aldri
    Noen ganger
    Ofte
    Det meste av tiden
    Alltid
50. For kvinner: Har du kun hatt dette ubehaget eller 
 smerten i forbindelse med menstruasjonsblødning 
 og ikke til andre tider?
    Nei
    Ja
    Ikke aktuelt fordi jeg ikke har menstruasjon
51. Når du hadde denne smerten, hvor ofte hemmet eller
 begrenset den daglige gjøremål (for eksempel arbeid,
 gjøremål i hjemmet eller sosiale aktiviteter?
    Sjelden/aldri
    Noen ganger
    Ofte
    Det meste av tiden
    Alltid
52. Har du hatt dette ubehaget eller smerten i 6 måneder
  eller lenger?
    Nei
    Ja
53. Hvor ofte ble ubehaget eller smerten i magen bedre
  eller forsvant etter  at du hadde hatt avføring?
    Sjelden/aldri
    Noen ganger
    Ofte
    Det meste av tiden
    Alltid
54. Når dette ubehaget eller smerten begynte, hadde du
  hyppigere avføring?
    Sjelden/aldri
    Noen ganger
    Ofte
    Det meste av tiden
    Alltid
55. Når dette ubehaget eller smerten begynte, hadde du
  sjeldnere avføring?
    Sjelden/aldri
    Noen ganger
    Ofte
    Det meste av tiden
    Alltid
56. Når dette ubehaget eller smerten begynte, hadde du
  løsere avføring?
    Sjelden/aldri
    Noen ganger
    Ofte
    Det meste av tiden
    Alltid
57. Når dette ubehaget eller smerten begynte, hvor ofte
  hadde du hardere avføring?
    Sjelden/aldri
    Noen ganger
    Ofte
    Det meste av tiden
    Alltid
58. I løpet av de siste 3 måneder, hvor ofte har du hatt
 færre enn tre (0-2) avføringer hver uke?
    Sjelden/aldri
    Noen ganger
    Ofte
    Det meste av tiden
    Alltid
59. I løpet av siste tre måneder, hvor ofte har du hatt
 hard eller klumpete avføring?
    Sjelden/aldri
    Ca. 25% av tiden
    Ca. 50% av tiden
    Ca. 75% av tiden 
    Alltid, 100% av tiden
60. I løpet av de siste 3 måneder, hvor ofte har du hatt
 4 eller fl ere avføringer i løpet av en dag?
    Sjelden/aldri
    Noen ganger
    Ofte
    Det meste av tiden
    Alltid
61. I løpet av de siste 3 måneder, hvor ofte har du hatt
 løs, grøtete eller vandig avføring?
    Sjelden/aldri
    Ca. 25% av tiden
    Ca. 50% av tiden
    Ca. 75% av tiden 
    Alltid, 100% av tiden
62. I løpet av de siste 3 måneder, hvor ofte har du vært
 oppblåst eller utspilt i magen?
    Aldri  
    Mindre enn 1 dag i måneden  
    En dag i måneden
    2-3 dager i måneden  
    En dag i uka
    Mer enn en dag i uka 
    Hver dag
63. I løpet av de siste 3 måneder, hvor ofte har du hatt
 så dårlig lukt av avføring eller luft fra endetarmen
 at det påvirket daglige gjøremål (f.eks. unngått å
 være med andre, bruke andres toalett)?
    Aldri  
    Mindre enn 1 dag i måneden  
    En dag i måneden
    2-3 dager i måneden  
    En dag i uka
    Mer enn en dag i uka 
    Hver dag
64. I løpet av siste 3 måneder, hvor ofte har du hatt
 vedvarende smerter i midten eller på høyre side
 øverst i magen?
    Aldri  ¤ Gå til spørsmål 69 
    Mindre enn 1 dag i måneden  
    En dag i måneden
    2-3 dager i måneden  
    En dag i uka
    Mer enn en dag i uka 
    Hver dag
65. Varte denne smerten 30 minutter eller lenger?
    Sjelden/aldri
    Noen ganger
    Ofte
    Det meste av tiden
    Alltid
66. Bygget denne smerten seg opp til en vedvarende,
 sterk smerte?
    Sjelden/aldri
    Noen ganger
    Ofte
    Det meste av tiden
    Alltid
67. Forsvant denne smerten fullstendig mellom hver
 gang den kom?
    Sjelden/aldri
    Noen ganger
    Ofte
    Det meste av tiden
    Alltid
68. Hindret denne smerten deg i vanlige aktiviteter,
 eller førte den til at du øyeblikkelig oppsøkte lege
 eller legevakt?
    Sjelden/aldri
    Noen ganger
    Ofte
    Det meste av tiden 
    Alltid
69. Dersom du drikker melk, får du da plager fra
 magen?
    Nei, ingen plager
    Lette plager   
    Middels store plager 
    Store plager
70. Dersom du får plager når du drikker melk, om lag
 når begynte plagene? 
 År: ……..  Måned: ………….         Husker ikke
71. Reagerer du med plager fra magen dersom du
 inntar spesiell mat eller drikke?
    Nei, ingen plager
    Lette plager 
    Middels store plager
    Store plager
72. Dersom du reagerer, hva slags mat eller drikke
 reagerer du på: 
………………………………………… 
…….……………………………………
  73. Har du mageplager NÅ som du ikke hadde før du fi kk Giardia-infeksjon? 
           Nei           Ja        Usikker
  Hvis ja, prøv å gradere dine symptomer den siste måneden i tabellen under:
  Angi på en skala fra 1 til 10:  0 = ingen symptomer og 10 = alvorlige symptomer 






 79. Nedsatt appetitt
  Synes du at du fi kk tilstrekkelig informasjon etter at du ble syk med giardia-infeksjon?














81. Fra Bergen legevakt
82. Fra sykehus
83. Fra Bergen kommune (nettsider,
      løpesedler i posten, informasjon
      gjennom avisem.v.)
  Synes du at du fi kk tilfredsstillende behandling etter at du ble syk med giardia-infeksjon?




















Jeg samtykker i at opplysingene ovenfor kan kobles med opplysninger om meg i offentlige helseregistre 
for forskningsformål (sett kryss): 
Jeg samtykker i at tidligere innhentede data om meg (avføringsprøver, blodprøver etc) i forbindelse med 
giardia-sykdom kan brukes i dette og senere forskningsprosjekter om giardia (sett kryss):
Informasjon og behandling
Mener du at du har hatt giardia-infeksjon?
 Nei       Ja       Usikker
Hvis ja: Når fi kk du giardia-infeksjonen?  Måned: ……………...  År: …………….
Hvis ja: Ble giardia-infeksjon bekreftet av lege?      Ja          Nei          Usikker
1. Sivilstand:
   Enslig    Gift/samboer   Skilt/separert   Enke/enkemann
 
2. Hva er det høyeste utdanningsnivå du har påbegynt?
  Grunnskole   Videregående skole    Universitet eller høyskole
  
3. Hvilken hovedinntektskilde har du?
   Arbeidstaker    Student/skoleelev/militær     Alderspensjonist 
   Selvstendig næringsdrivende    Arbeidsledig    Annet
   Hjemmeværende    Uføretrygdet
  
4. Var du student høsten 2004?
   Nei                     Ja, fulltid          Ja, deltid
5. For kvinner: Er du gravid nå?
   Nei         Ja                      Usikker
Institutt for samfunnsmedisinske fag og Institutt for indremedisin
Universitetet i Bergen
Kalfarveien 31, 5018 BERGEN, Tlf: 55 58 61 00
Hvor sannsynlig er det at du døser av eller sovner i følgende situasjoner, i motsetning til kun å føle deg trett? 
Spørsmålene gjelder din vanlige måte å reagere på i den senere tid. Selv om du ikke har gjort noe av dette i den siste 








Stor sjanse for 
å døse/sovne
  6.  Sitte og lese
  7.  Se på TV
  8.  Sitte, inaktiv på et offentlig sted
       (for eksempel teater eller et møte)
  9.  Som passasjer på en en-times biltur uten pause
10.  Legge deg for å hvile om ettermiddagen hvis
       omstendighetene tillater det
11.  Sitte og snakke med noen
12.  Sitte stille etter lunsj (uten å ha inntatt alkohol)
13.  I en bil, som har stoppet for noen få minutter i
       trafi kken
  14. Hvor mye søvn trenger du for å være opplagt?   ……….. timer  
  15. I løpet av siste måned, hvor ofte har du vært plaget av søvnløshet?
              Aldri eller sjelden           1-2 ganger i måneden       Omtrent en gang i uken       Mer enn en gang i uken












Vi vil gjerne vite om du har følt deg sliten, svak eller i mangel av overskudd den siste måneden. Vennligst besvar 
ALLE spørsmålene ved å krysse av for det svaret du synes passer best for deg. Vi ønsker at du besvarer alle 
spørsmålene selv om du ikke har hatt slike problemer. Hvis du har følt deg sliten lenge, ber vi om at du
sammenlikner deg med hvordan du følte deg sist du var bra. (Ett kryss for hver linje) 
16. Har du problemer med at du føler deg sliten?
   Mindre enn vanlig           Ikke mer enn vanlig           Mer enn vanlig          Mye mer enn vanlig
17. Trenger du mer hvile?
   Nei, mindre enn vanlig          Ikke mer enn vanlig           Mer enn vanlig          Mye mer enn vanlig
18. Føler du deg søvnig eller døsig?
   Mindre enn vanlig             Ikke mer enn vanlig           Mer enn vanlig          Mye mer enn vanlig
19. Har du problemer med å komme i gang med ting?
   Mindre enn vanlig           Ikke mer enn vanlig           Mer enn vanlig          Mye mer enn vanlig
20. Mangler du overskudd?
   Ikke i det hele tatt           Ikke mer enn vanlig           Mer enn vanlig          Mye mer enn vanlig
21. Har du redusert styrke i musklene dine?
   Ikke i det hele tatt           Ikke mer enn vanlig           Mer enn vanlig          Mye mer enn vanlig
22. Føler du deg svak?
   Mindre enn vanlig           Som vanlig                         Mer enn vanlig          Mye mer enn vanlig
23. Har du vansker med å konsentrere deg?
   Mindre enn vanlig           Som vanlig                         Mer enn vanlig          Mye mer enn vanlig
24. Forsnakker du deg i samtaler?
   Mindre enn vanlig           Ikke mer enn vanlig           Mer enn vanlig          Mye mer enn vanlig
25. Er det vanskeligere å fi nne det rette ordet?
   Mindre enn vanlig           Ikke mer enn vanlig           Mer enn vanlig          Mye mer enn vanlig
26. Hvordan er hukommelsen din?
   Bedre enn vanlig           Ikke verre enn vanlig         Verre enn vanlig        Mye verre enn vanlig
27. Hvis du føler deg sliten for tiden, omtrent hvor lenge har det vart? (Ett kryss)
    Mindre enn én måned    Fra ett år inntil tre år
    Fra én måned inntil seks måneder    Tre år eller mer (før oktober 2004)
    Fra seks måneder inntil ett år
 
 
28. Hvis du føler deg sliten for tiden, omtrent hvor mye av tiden kjenner du det? (Ett kryss)
    25 % av tiden    75 % av tiden
    50 % av tiden    Hele tiden
Slitenhet
 29. Har du eller har du hatt astma?                    Nei      Ja       Usikker
30. Hvis ja, er dette bekreftet av lege?       Nei      Ja
31. Har du brukt astma-medisiner siste måned?
(spray, pulver/væske til inhalasjon, tabletter)      Nei      Ja 
32. Har du eller har du hatt høysnue eller neseallergi?     Nei      Ja       Usikker
Astma og allergi
Mageplager siste tre måneder
33. I løpet av de siste 3 måneder, hvor ofte har du følt
 deg ubehagelig mett etter et vanlig stort måltid?
      Aldri  ¤ Gå til spørsmål 35
      Mindre enn 1 dag i måneden  
      En dag i måneden
      2-3 dager i måneden  
      En dag i uka
      Mer enn en dag i uka 
      Hver dag
34. Har du hatt denne ubehagelige metthets-følelsen
 etter måltid i 6 måneder eller lenger? 
      Nei
      Ja
35. I løpet av de siste 3 måneder, hvor ofte har du ikke
 kunnet fullføre et vanlig stort måltid?
      Aldri  ¤ Gå til spørsmål 37
      Mindre enn 1 dag i måneden  
      En dag i måneden
      2-3 dager i måneden  
      En dag i uka
      Mer enn en dag i uka 
      Hver dag
36. Har du hatt dette problemet med ikke å kunne
 fullføre et vanlig stort måltid i 6 måneder eller lenger? 
      Nei
      Ja
37. I løpet av de siste 3 måneder, hvor ofte har du hatt
 smerter eller brenning midt i magen, over navlen, men
  ikke i brystet?
      Aldri  ¤ Gå til spørsmål 46 (på neste side)
      Mindre enn 1 dag i måneden  
      En dag i måneden
      2-3 dager i måneden  
      En dag i uka
      Mer enn en dag i uka 
      Hver dag
38. Har du hatt denne smerten eller brenningen i
 6 måneder eller lenger? 
    Nei
    Ja
39. Kom og forsvant denne smerten eller
 brenningen fullstendig i løpet av samme dag?
    Sjelden/aldri
    Noen ganger
    Ofte
    Det meste av tiden
    Alltid
40. Hvor alvorlig var vanligvis smerten eller
 brenningen i midten av magen, over navlen?
    Svært mild
    Mild
    Moderat
    Sterk 
    Svært sterk
41. Ble denne smerten eller brenningen påvirket av
 spising?
    Ikke påvirket av spising
    Mer smerter etter spising
    Mindre smerter etter spising
42. Ble denne smerten eller brenningen lindret av å
 ta syrenøytraliserende midler?
    Sjelden/aldri
    Noen ganger
    Ofte
    Det meste av tiden
    Alltid
43. Ble denne smerten eller brenningen vanligvis
 bedre eller forsvant den etter at du hadde hatt
 avføring eller luftavgang fra endetarmen?
    Sjelden/aldri
    Noen ganger
    Ofte
    Det meste av tiden
    Alltid
44. Når denne smerten eller brenningen begynte,
  hadde du vanligvis endring i antall avføringer
  (enten hyppigere eller sjeldnere avføring)?
    Sjelden/aldri
    Noen ganger
    Ofte
    Det meste av tiden
    Alltid
45. Når denne smerten eller brenningen begynte,
  hadde du vanligvis løsere eller hardere avføring?
    Sjelden/aldri
    Noen ganger
    Ofte
    Det meste av tiden
    Alltid
46. Har lege diagnostisert sykdom i spiserør eller
  magesekk hos deg siste 3 år? 
    Nei
    Ja
Hvis ja, hva slags sykdom: 
………………………………………………
47. I løpet av siste 3 måneder, hvor ofte har du hatt
 plagsom kvalme?
    Aldri  
    Mindre enn 1 dag i måneden  
    En dag i måneden
    2-3 dager i måneden  
    En dag i uka
    Mer enn en dag i uka 
    Hver dag
48. I løpet av siste tre måneder, hvor ofte har du hatt
 ubehag eller smerter noe sted i magen?
    Aldri  ¤ Gå til spørsmål 58 
    Mindre enn 1 dag i måneden  
    En dag i måneden
    2-3 dager i måneden  
    En dag i uka
    Mer enn en dag i uka 
    Hver dag
49. Har du hatt kun smerter (ikke ubehag eller en
  blanding av ubehag og smerter)?
    Sjelden/aldri
    Noen ganger
    Ofte
    Det meste av tiden
    Alltid
50. For kvinner: Har du kun hatt dette ubehaget eller 
 smerten i forbindelse med menstruasjonsblødning 
 og ikke til andre tider?
    Nei
    Ja
    Ikke aktuelt fordi jeg ikke har menstruasjon
51. Når du hadde denne smerten, hvor ofte hemmet eller
 begrenset den daglige gjøremål (for eksempel arbeid,
 gjøremål i hjemmet eller sosiale aktiviteter?
    Sjelden/aldri
    Noen ganger
    Ofte
    Det meste av tiden
    Alltid
52. Har du hatt dette ubehaget eller smerten i 6 måneder
  eller lenger?
    Nei
    Ja
53. Hvor ofte ble ubehaget eller smerten i magen bedre
  eller forsvant etter  at du hadde hatt avføring?
    Sjelden/aldri
    Noen ganger
    Ofte
    Det meste av tiden
    Alltid
54. Når dette ubehaget eller smerten begynte, hadde du
  hyppigere avføring?
    Sjelden/aldri
    Noen ganger
    Ofte
    Det meste av tiden
    Alltid
55. Når dette ubehaget eller smerten begynte, hadde du
  sjeldnere avføring?
    Sjelden/aldri
    Noen ganger
    Ofte
    Det meste av tiden
    Alltid
56. Når dette ubehaget eller smerten begynte, hadde du
  løsere avføring?
    Sjelden/aldri
    Noen ganger
    Ofte
    Det meste av tiden
    Alltid
57. Når dette ubehaget eller smerten begynte, hvor ofte
  hadde du hardere avføring?
    Sjelden/aldri
    Noen ganger
    Ofte
    Det meste av tiden
    Alltid
58. I løpet av de siste 3 måneder, hvor ofte har du hatt
 færre enn tre (0-2) avføringer hver uke?
    Sjelden/aldri
    Noen ganger
    Ofte
    Det meste av tiden
    Alltid
59. I løpet av siste tre måneder, hvor ofte har du hatt
 hard eller klumpete avføring?
    Sjelden/aldri
    Ca. 25% av tiden
    Ca. 50% av tiden
    Ca. 75% av tiden 
    Alltid, 100% av tiden
60. I løpet av de siste 3 måneder, hvor ofte har du hatt
 4 eller fl ere avføringer i løpet av en dag?
    Sjelden/aldri
    Noen ganger
    Ofte
    Det meste av tiden
    Alltid
61. I løpet av de siste 3 måneder, hvor ofte har du hatt
 løs, grøtete eller vandig avføring?
    Sjelden/aldri
    Ca. 25% av tiden
    Ca. 50% av tiden
    Ca. 75% av tiden 
    Alltid, 100% av tiden
62. I løpet av de siste 3 måneder, hvor ofte har du vært
 oppblåst eller utspilt i magen?
    Aldri  
    Mindre enn 1 dag i måneden  
    En dag i måneden
    2-3 dager i måneden  
    En dag i uka
    Mer enn en dag i uka 
    Hver dag
63. I løpet av de siste 3 måneder, hvor ofte har du hatt
 så dårlig lukt av avføring eller luft fra endetarmen
 at det påvirket daglige gjøremål (f.eks. unngått å
 være med andre, bruke andres toalett)?
    Aldri  
    Mindre enn 1 dag i måneden  
    En dag i måneden
    2-3 dager i måneden  
    En dag i uka
    Mer enn en dag i uka 
    Hver dag
64. I løpet av siste 3 måneder, hvor ofte har du hatt
 vedvarende smerter i midten eller på høyre side
 øverst i magen?
    Aldri  ¤ Gå til spørsmål 69 
    Mindre enn 1 dag i måneden  
    En dag i måneden
    2-3 dager i måneden  
    En dag i uka
    Mer enn en dag i uka 
    Hver dag
65. Varte denne smerten 30 minutter eller lenger?
    Sjelden/aldri
    Noen ganger
    Ofte
    Det meste av tiden
    Alltid
66. Bygget denne smerten seg opp til en vedvarende,
 sterk smerte?
    Sjelden/aldri
    Noen ganger
    Ofte
    Det meste av tiden
    Alltid
67. Forsvant denne smerten fullstendig mellom hver
 gang den kom?
    Sjelden/aldri
    Noen ganger
    Ofte
    Det meste av tiden
    Alltid
68. Hindret denne smerten deg i vanlige aktiviteter,
 eller førte den til at du øyeblikkelig oppsøkte lege
 eller legevakt?
    Sjelden/aldri
    Noen ganger
    Ofte
    Det meste av tiden 
    Alltid
69. Dersom du drikker melk, får du da plager fra
 magen?
    Nei, ingen plager
    Lette plager   
    Middels store plager 
    Store plager
70. Dersom du får plager når du drikker melk, om lag
 når begynte plagene? 
 År: ……..  Måned: ………….         Husker ikke
71. Reagerer du med plager fra magen dersom du
 inntar spesiell mat eller drikke?
    Nei, ingen plager
    Lette plager 
    Middels store plager
    Store plager
72. Dersom du reagerer, hva slags mat eller drikke
 reagerer du på: 
………………………………………… 
…….……………………………………
 Jeg samtykker i at opplysingene ovenfor kan kobles med opplysninger om meg i offentlige helseregistre for 
forskningsformål (sett kryss): 
  Takk for hjelpen!
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Takk for hjelpen!
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